


**CUMULATIVE
SUPPLEMENT 4
APRIL 2014**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Cumulative Supplement 4

April 2014

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

**CUMULATIVE SUPPLEMENT 4
April 2014**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885			
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)			
MULTISOURCE	13194 (84.0%)	13345 (84.0%)			
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)			
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)			
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	20	12			
NUMBER OF APPLICANTS	866	873			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM

AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

>D> PHRENILIN FORTE

>D> + VALEANT 650MG;50MG A088831 001 Jun 19, 1985 Apr DISC

>A> @ 650MG;50MG A088831 001 Jun 19, 1985 Apr DISC

TABLET;ORAL

>D> BUTAPAP

>D> + MIKART 650MG;50MG A089988 001 Oct 26, 1992 Apr DISC

>A> @ 650MG;50MG A089988 001 Oct 26, 1992 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

>D> ESGIC-PLUS

>D> + MIKART 500MG;50MG;40MG A040085 001 Mar 28, 1996 Apr DISC

>A> @ 500MG;50MG;40MG A040085 001 Mar 28, 1996 Apr DISC

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D> + MIKART 750MG;50MG;40MG A040496 001 Dec 23, 2003 Apr DISC

>A> @ 750MG;50MG;40MG A040496 001 Dec 23, 2003 Apr DISC

@ MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar DISC

AA + VINTAGE PHARMS 325MG;50MG;40MG A040511 001 Aug 27, 2003 Mar CRLD

>D> AA 500MG;50MG;40MG A040513 001 Aug 25, 2003 Apr DISC

>A> @ 500MG;50MG;40MG A040513 001 Aug 25, 2003 Apr DISC

@ WATSON LABS 500MG;50MG;40MG A040267 001 Jul 30, 1998 Jan DISC

ESGIC-PLUS

>D> AA + MIKART 500MG;50MG;40MG A089451 001 May 23, 1988 Apr DISC

>A> @ 500MG;50MG;40MG A089451 001 May 23, 1988 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

PHRENILIN WITH CAFFEINE AND CODEINE

@ VALEANT 325MG;50MG;40MG;30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG/15ML;7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC

>D> AA + MIKART 500MG/15ML;7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC

>A> @ 500MG/15ML;7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC

>D> AA PHARM ASSOC 500MG/15ML;7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC

>A> @ 500MG/15ML;7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC

AA VINTAGE PHARMS 325MG/15ML;7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN

>D> AA 500MG/15ML;7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC

>A> @ 500MG/15ML;7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC

TABLET;ORAL

ANEXSIA

@ MALLINCKRODT 500MG;5MG A089160 001 Apr 23, 1987 Jan DISC

@ 750MG;10MG A040468 001 Oct 31, 2002 Jan DISC

ANEXSIA 7.5/650

@ MALLINCKRODT 650MG;7.5MG A089725 001 Sep 30, 1987 Jan DISC

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D> AA AMNEAL PHARMS NY 500MG;5MG A040729 001 Aug 25, 2006 Apr DISC

>A> @ 500MG;5MG A040729 001 Aug 25, 2006 Apr DISC

>D> AA 500MG;7.5MG A040748 001 Aug 25, 2006 Apr DISC

>A> @ 500MG;7.5MG A040748 001 Aug 25, 2006 Apr DISC

>D> AA 500MG;10MG A040813 001 Feb 23, 2007 Apr DISC

>A> @ 500MG;10MG A040813 001 Feb 23, 2007 Apr DISC

>D> AA 650MG;7.5MG A040754 001 Aug 25, 2006 Apr DISC

>A> @ 650MG;7.5MG A040754 001 Aug 25, 2006 Apr DISC

>D> AA 650MG;10MG A040757 001 Aug 25, 2006 Apr DISC

>A> @ 650MG;10MG A040757 001 Aug 25, 2006 Apr DISC

>D> AA 750MG;7.5MG A040769 001 Aug 28, 2006 Apr DISC

>A> @ 750MG;7.5MG A040769 001 Aug 28, 2006 Apr DISC

>D> AA CARACO 500MG;5MG A090265 001 Dec 23, 2008 Apr DISC

>A> @ 500MG;5MG A090265 001 Dec 23, 2008 Apr DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	AA		500MG;7.5MG	A090265	002	Dec 23, 2008	Apr	DISC	
>A>	@		500MG;7.5MG	A090265	002	Dec 23, 2008	Apr	DISC	
>D>	AA		500MG;10MG	A090265	003	Dec 23, 2008	Apr	DISC	
>A>	@		500MG;10MG	A090265	003	Dec 23, 2008	Apr	DISC	
>D>	AA		650MG;7.5MG	A090380	001	Dec 23, 2008	Apr	DISC	
>A>	@		650MG;7.5MG	A090380	001	Dec 23, 2008	Apr	DISC	
>D>	AA		650MG;10MG	A090380	002	Dec 23, 2008	Apr	DISC	
>A>	@		650MG;10MG	A090380	002	Dec 23, 2008	Apr	DISC	
>D>	AA		660MG;10MG	A090380	003	Dec 23, 2008	Apr	DISC	
>A>	@		660MG;10MG	A090380	003	Dec 23, 2008	Apr	DISC	
>D>	AA		750MG;7.5MG	A090380	004	Dec 23, 2008	Apr	DISC	
>A>	@		750MG;7.5MG	A090380	004	Dec 23, 2008	Apr	DISC	
	@	MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995	Jan	DISC	
	@		500MG;7.5MG	A040201	001	Feb 27, 1998	Jan	DISC	
	@		500MG;10MG	A040201	002	Feb 27, 1998	Jan	DISC	
	@		650MG;10MG	A040084	004	Oct 16, 1996	Jan	DISC	
	@		660MG;10MG	A040084	003	Jul 29, 1996	Jan	DISC	
	@		750MG;7.5MG	A040084	001	Jun 01, 1995	Jan	DISC	
>D>	AA	+	MIKART	500MG;7.5MG	A089699	001	Aug 25, 1989	Apr	DISC
>A>	@		500MG;7.5MG	A089699	001	Aug 25, 1989	Apr	DISC	
>D>	AA	+	650MG;7.5MG	A089689	001	Jun 29, 1988	Apr	DISC	
>A>	@		650MG;7.5MG	A089689	001	Jun 29, 1988	Apr	DISC	
>D>	AA	+	650MG;10MG	A081223	001	May 29, 1992	Apr	DISC	
>A>	@		650MG;10MG	A081223	001	May 29, 1992	Apr	DISC	
	AA		VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CAHN
	AA		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CAHN	
	AA		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CAHN	
>D>	AA		500MG;2.5MG	A040144	002	Apr 25, 1997	Apr	DISC	
>A>	@		500MG;2.5MG	A040144	002	Apr 25, 1997	Apr	DISC	
>D>	AA		500MG;5MG	A089971	001	Dec 02, 1988	Apr	DISC	
>A>	@		500MG;5MG	A089971	001	Dec 02, 1988	Apr	DISC	
>D>	AA		500MG;7.5MG	A040144	001	Feb 22, 1996	Apr	DISC	
>A>	@		500MG;7.5MG	A040144	001	Feb 22, 1996	Apr	DISC	
>D>	AA		500MG;10MG	A040356	001	May 31, 2000	Apr	DISC	
>A>	@		500MG;10MG	A040356	001	May 31, 2000	Apr	DISC	
	@		650MG;7.5MG	A040155	001	Apr 14, 1997	Jan	DISC	
>D>	AA		650MG;10MG	A040143	001	Feb 22, 1996	Apr	DISC	
>A>	@		650MG;10MG	A040143	001	Feb 22, 1996	Apr	DISC	
>D>	AA		660MG;10MG	A040358	001	May 31, 2000	Apr	DISC	
>A>	@		660MG;10MG	A040358	001	May 31, 2000	Apr	DISC	
	@		750MG;7.5MG	A040157	001	Apr 12, 1996	Jan	DISC	
>D>	AA		WATSON LABS	500MG;2.5MG	A081079	001	Aug 30, 1991	Apr	DISC
>A>	@		500MG;2.5MG	A081079	001	Aug 30, 1991	Apr	DISC	
>D>	AA		500MG;5MG	A089883	001	Dec 01, 1988	Apr	DISC	
>A>	@		500MG;5MG	A089883	001	Dec 01, 1988	Apr	DISC	
	@		500MG;7.5MG	A081080	001	Aug 30, 1991	Jan	DISC	
>D>	AA		500MG;10MG	A040148	002	Feb 14, 1997	Apr	DISC	
>A>	@		500MG;10MG	A040148	002	Feb 14, 1997	Apr	DISC	
>D>	AA		650MG;7.5MG	A040094	001	Sep 29, 1995	Apr	DISC	
>A>	@		650MG;7.5MG	A040094	001	Sep 29, 1995	Apr	DISC	
>D>	AA		650MG;10MG	A040094	002	Sep 29, 1995	Apr	DISC	
>A>	@		650MG;10MG	A040094	002	Sep 29, 1995	Apr	DISC	
>D>	AA		660MG;10MG	A040094	003	Aug 08, 2000	Apr	DISC	
>A>	@		660MG;10MG	A040094	003	Aug 08, 2000	Apr	DISC	
	@		750MG;7.5MG	A081083	001	Aug 30, 1991	Jan	DISC	
>D>	AA	+	750MG;10MG	A040094	004	Mar 22, 1999	Apr	DISC	
>A>	@		750MG;10MG	A040094	004	Mar 22, 1999	Apr	DISC	
>D>	AA		WATSON LABS FLORIDA	660MG;10MG	A040495	001	May 28, 2003	Apr	DISC
>A>	@		660MG;10MG	A040495	001	May 28, 2003	Apr	DISC	
			LORTAB						
>D>	AA		UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Apr	DISC
>A>	@		500MG;5MG	A087722	001	Jul 09, 1982	Apr	DISC	
>D>	AA	+	500MG;10MG	A040100	001	Jan 26, 1996	Apr	DISC	
>A>	@		500MG;10MG	A040100	001	Jan 26, 1996	Apr	DISC	
>D>			ZYDONE						
>D>	+		VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998	Apr	DISC
>A>	@		400MG;5MG	A040288	001	Nov 27, 1998	Apr	DISC	
>D>	+		400MG;7.5MG	A040288	002	Nov 27, 1998	Apr	DISC	
>A>	@		400MG;7.5MG	A040288	002	Nov 27, 1998	Apr	DISC	
>D>	+		400MG;10MG	A040288	003	Nov 27, 1998	Apr	DISC	
>A>	@		400MG;10MG	A040288	003	Nov 27, 1998	Apr	DISC	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	DURAMED PHARMS BARR	500MG;5MG	A 040289	001	Mar 16, 1999	Apr	DISC
>A>		@	500MG;5MG	A 040289	001	Mar 16, 1999	Apr	DISC
		@ MALLINCKRODT	500MG;5MG	A 040257	001	Aug 04, 1998	Jan	DISC
>D>	AA	VINTAGE PHARMS	500MG;5MG	A 040106	001	Jul 30, 1996	Apr	DISC
>A>		@	500MG;5MG	A 040106	001	Jul 30, 1996	Apr	DISC
		@ WATSON LABS	500MG;5MG	A 040234	001	Oct 30, 1997	Jan	DISC
>D>		ROXILOX						
>D>	AA	ROXANE	500MG;5MG	A 040061	001	Jul 03, 1995	Apr	DISC
>A>		@	500MG;5MG	A 040061	001	Jul 03, 1995	Apr	DISC
>D>		TYLOX						
>D>	AA	+ JANSSEN PHARMS	500MG;5MG	A 088790	001	Dec 12, 1984	Apr	DISC
>A>		@	500MG;5MG	A 088790	001	Dec 12, 1984	Apr	DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	AMNEAL PHARMS NY	500MG;7.5MG	A 040789	001	Nov 27, 2007	Apr	DISC
>A>		@	500MG;7.5MG	A 040789	001	Nov 27, 2007	Apr	DISC
>D>	AA		650MG;10MG	A 040789	002	Nov 27, 2007	Apr	DISC
>A>		@	650MG;10MG	A 040789	002	Nov 27, 2007	Apr	DISC
>D>	AA	COASTAL PHARMS	500MG;7.5MG	A 090177	005	Oct 20, 2008	Apr	DISC
>A>		@	500MG;7.5MG	A 090177	005	Oct 20, 2008	Apr	DISC
>D>	AA		650MG;10MG	A 090177	006	Oct 20, 2008	Apr	DISC
>A>		@	650MG;10MG	A 090177	006	Oct 20, 2008	Apr	DISC
>D>	AA	MALLINCKRODT	500MG;7.5MG	A 040550	001	Jun 30, 2004	Apr	DISC
>A>		@	500MG;7.5MG	A 040550	001	Jun 30, 2004	Apr	DISC
>D>	AA		650MG;10MG	A 040550	002	Jun 30, 2004	Apr	DISC
>A>		@	650MG;10MG	A 040550	002	Jun 30, 2004	Apr	DISC
>D>		+ MIKART	400MG;5MG	A 040687	001	Apr 27, 2006	Apr	DISC
>A>		@	400MG;5MG	A 040687	001	Apr 27, 2006	Apr	DISC
>D>		+	400MG;7.5MG	A 040698	001	Apr 27, 2006	Apr	DISC
>A>		@	400MG;7.5MG	A 040698	001	Apr 27, 2006	Apr	DISC
>D>		+	400MG;10MG	A 040692	001	Apr 27, 2006	Apr	DISC
>A>		@	400MG;10MG	A 040692	001	Apr 27, 2006	Apr	DISC
>D>			500MG;10MG	A 040676	001	Apr 19, 2006	Apr	DISC
>A>		@	500MG;10MG	A 040676	001	Apr 19, 2006	Apr	DISC
		@ WATSON LABS	500MG;7.5MG	A 040371	001	Dec 29, 2000	Jan	DISC
		@	650MG;10MG	A 040371	002	Dec 29, 2000	Jan	DISC
		PERCOCET						
		@ VINTAGE PHARMS LLC	500MG;7.5MG	A 040341	001	Jul 26, 1999	Jan	DISC
		@	650MG;10MG	A 040341	002	Jul 26, 1999	Jan	DISC

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

		+ MALLINCKRODT INC	325MG;7.5MG	N 204031	001	Mar 11, 2014	Mar	NEWA
--	--	--------------------	-------------	----------	-----	--------------	-----	------

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

>D>	AB	GAVIS PHARMS	650MG;EQ 25MG BASE	A 076202	001	Aug 02, 2002	Apr	DISC
>A>		@	650MG;EQ 25MG BASE	A 076202	001	Aug 02, 2002	Apr	DISC
>D>	AB	+ WATSON LABS	650MG;EQ 25MG BASE	A 074699	001	Mar 24, 2000	Apr	DISC
>A>		@	650MG;EQ 25MG BASE	A 074699	001	Mar 24, 2000	Apr	DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A>	AB	ALLIED PHARMA INC	325MG;37.5MG	A 202076	001	Mar 30, 2012	Apr	CAHN
>D>	AB	ALVOGEN INC	325MG;37.5MG	A 202076	001	Mar 30, 2012	Apr	CAHN
	AB	APOTEX INC	325MG;37.5MG	A 078778	001	Apr 07, 2014	Mar	NEWA

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN		INNOPHARMA LICENSING	10%	A 204674	001	Feb 11, 2014	Jan	NEWA
----	--	----------------------	-----	----------	-----	--------------	-----	------

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE; ORAL
SEMPREX-D

>D>	+	ACTIENT PHARMS	8MG; 60MG	N019806	001	Mar 25, 1994	Apr CAHN
>A>	+	AUXILIUM PHARMS LLC	8MG; 60MG	N019806	001	Mar 25, 1994	Apr CAHN

ACYCLOVIRCAPSULE; ORAL
ACYCLOVIR

AB		CADILA PHARMS LTD	200MG	A201445	001	Mar 06, 2014	Feb NEWA
		TABLET; BUCCAL SITAVIG					
>D>		@ BIOALLIANCE PHARMA	50MG	N203791	001	Apr 12, 2013	Apr CAHN
>A>	+	INNOCUTIS HOLDINGS	50MG	N203791	001	Apr 12, 2013	Apr CMFD
>A>	+		50MG	N203791	001	Apr 12, 2013	Apr CAHN

ACYCLOVIR SODIUMINJECTABLE; INJECTION
ACYCLOVIR SODIUM

	+	BEDFORD	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb CRLD
		@ HIKMA MAPLE	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997	Feb DISC
		@	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997	Feb DISC

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

AP		AGILA SPECLTS	3MG/ML	A078640	001	Mar 21, 2014	Mar NEWA
AP			3MG/ML	A078686	001	May 13, 2009	Feb CAHN
AP		HOSPIRA INC	3MG/ML	A203883	001	Mar 24, 2014	Mar NEWA
AP		SAGENT STRIDES	3MG/ML	A090212	001	Mar 28, 2014	Mar NEWA

ALPRAZOLAMTABLET; ORAL
ALPRAZOLAM

AB		VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb CAHN
AB			0.5MG	A090248	002	Sep 17, 2010	Feb CAHN
AB			1MG	A090248	003	Sep 17, 2010	Feb CAHN
AB			2MG	A090248	004	Sep 17, 2010	Feb CAHN
		TABLET, EXTENDED RELEASE; ORAL ALPRAZOLAM					
AB		ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan CAHN
		@	0.5MG	A077979	001	Feb 28, 2007	Jan CAHN
AB			1MG	A077725	002	Jul 31, 2006	Jan CAHN
		@	1MG	A077979	002	Feb 28, 2007	Jan CAHN
AB			2MG	A077725	004	Jul 31, 2006	Jan CAHN
		@	2MG	A077979	003	Feb 28, 2007	Jan CAHN
AB			3MG	A077725	003	Jul 31, 2006	Jan CAHN
		@	3MG	A077979	004	Feb 28, 2007	Jan CAHN

ALPROSTADILINJECTABLE; INJECTION
EDEX

>D>		@ ACTIENT PHARMS	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr CAHN
>D>	AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr CAHN
>D>	+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr CAHN
>D>	AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr CAHN
>D>	+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr CAHN
>D>	AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr CAHN
>D>	+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr CAHN
>A>		@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr CAHN
>A>	AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr CAHN
>A>	+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr CAHN
>A>	AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr CAHN
>A>	+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr CAHN
>A>	AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr CAHN
>A>	+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	+	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb	CRLD
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb	CRLD

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	@	PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	Feb	DISC
	@		EQ 5MG BASE	A078131	002	Sep 04, 2007	Feb	DISC
	@		EQ 10MG BASE	A078131	003	Sep 04, 2007	Feb	DISC
>A>	AB	VIVIMED LABS	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr	CAHN
>A>	AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr	CAHN
>A>	AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr	CAHN
>D>	AB	WORLD GEN	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr	CAHN
>D>	AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr	CAHN
>D>	AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr	CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014	Feb	NEWA
AB			EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014	Feb	NEWA
AB			EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014	Feb	NEWA
AB			EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014	Feb	NEWA
AB			EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014	Feb	NEWA
AB			EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014	Feb	NEWA
AB			EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014	Feb	NEWA
AB			EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014	Feb	NEWA
AB			EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014	Feb	NEWA
AB			EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014	Feb	NEWA
AB			EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014	Feb	NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204496	001	Mar 28, 2014	Mar	NEWA
AP		WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan	NEWA

AMOXICILLIN

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

>A>	+	PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008	Apr	CAHN
>D>	+	SHIONOGI INC	775MG	N050813	001	Jan 23, 2008	Apr	CAHN

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB		SANDOZ	500MG,N/A,N/A,N/A,500MG,N/A,N/A,N/A,30MG	A202588	001	Mar 04, 2014	Feb	NEWA
----	--	--------	--	---------	-----	--------------	-----	------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	GASTROENTERO	500MG,N/A,N/A,N/A,500MG,N/A,N/A,N/A,20MG	N050824	001	Feb 08, 2011	Mar	CDFR
---	--------------	--	---------	-----	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D>	@	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003	Apr	CMFD
>A>	AB		1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003	Apr	CMFD
>D>	@		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003	Apr	CMFD
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003	Apr	CMFD
>D>	@		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003	Apr	CMFD
>A>	AB		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003	Apr	CMFD
>D>	@		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003	Apr	CMFD
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003	Apr	CMFD

AMPICILLIN SODIUMINJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Mar	NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb	CAHN
AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb	CAHN
AP		EQ 10GM BASE/VIAL	A201404	001	Dec 20, 2013	Jan	CPOT
AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb	CAHN
AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb	CAHN
AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb	CAHN
AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Mar	NEWA
AP		EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Mar	NEWA
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Mar	NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUMINJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Mar	NEWA
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Mar	NEWA
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Mar	NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005	Feb	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005	Feb	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006	Feb	CAHN

APREMILASTTABLET; ORAL
OTEZLA

CELGENE CORP

10MG
20MG
+

N205437	001	Mar 21, 2014	Mar	NEWA
N205437	002	Mar 21, 2014	Mar	NEWA
N205437	003	Mar 21, 2014	Mar	NEWA

ASENAPINE MALEATETABLET; SUBLINGUAL
SAPHRIS

FOREST LABS INC

EQ 5MG BASE
+ EQ 10MG BASE

N022117	001	Aug 13, 2009	Feb	CAHN
N022117	002	Aug 13, 2009	Feb	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ WATSON LABS 325MG; 50MG; 40MG; 30MG

A074359	001	Aug 31, 1995	Mar	DISC
---------	-----	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

@ STEVENS J 385MG; 30MG; 25MG

@ 770MG; 60MG; 50MG

A074988	001	Apr 30, 1999	Mar	DISC
A074988	002	Apr 30, 1999	Mar	DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@ MIRROR PHARMS 325MG; 200MG; 16MG

@ PROSAM LABS 325MG; 200MG; 16MG

A040860	001	Jan 07, 2010	Mar	DISC
A040283	001	Dec 29, 1998	Mar	DISC

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

>A>	AB	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014	Apr	NEWA
>A>	AB		EQ 150MG BASE	A091673	002	Apr 22, 2014	Apr	NEWA
>A>	AB		EQ 200MG BASE	A091673	003	Apr 22, 2014	Apr	NEWA
>A>	AB		EQ 300MG BASE	A091673	004	Apr 22, 2014	Apr	NEWA
		REYATAZ						
>D>	AB	BRISTOL MYERS SQUIBB	EQ 100MG BASE	N021567	001	Jun 20, 2003	Apr	CFTG
>A>	AB		EQ 100MG BASE	N021567	001	Jun 20, 2003	Apr	CFTG
>D>			EQ 150MG BASE	N021567	002	Jun 20, 2003	Apr	CFTG
>A>	AB		EQ 150MG BASE	N021567	002	Jun 20, 2003	Apr	CFTG
>D>			EQ 200MG BASE	N021567	003	Jun 20, 2003	Apr	CFTG
>A>	AB		EQ 200MG BASE	N021567	003	Jun 20, 2003	Apr	CFTG
>D>			EQ 300MG BASE	N021567	004	Oct 16, 2006	Apr	CFTG

		CAPSULE;ORAL							
		REYATAZ							
>A>	AB	+	EQ 300MG BASE		N021567	004	Oct 16, 2006	Apr	CFTG
		<u>ATENOLOL</u>							
		TABLET;ORAL							
		ATENOLOL							
>A>	AB	MYLAN	50MG		A073457	003	Jan 24, 1992	Apr	CMS1
		<u>ATOVAQUONE</u>							
		SUSPENSION;ORAL							
		ATOVAQUONE							
AB		AMNEAL PHARMS	750MG/5ML		A202960	001	Mar 18, 2014	Mar	NEWA
		MEPRON							
AB	+	GLAXOSMITHKLINE LLC	750MG/5ML		N020500	001	Feb 08, 1995	Mar	CFTG
		<u>AZELASTINE HYDROCHLORIDE</u>							
		SPRAY;NASAL							
		AZELASTINE HYDROCHLORIDE							
>A>	AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY		A202743	001	May 08, 2014	Apr	NEWA
		<u>AZILSARTAN KAMEDOXOMIL</u>							
		TABLET;ORAL							
		EDARBI							
		ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL		N200796	001	Feb 25, 2011	Feb	CAHN
	+		EQ 80MG MEDOXOMIL		N200796	002	Feb 25, 2011	Feb	CAHN
		<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE</u>							
		TABLET;ORAL							
		EDARBYCLOL							
		ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL;12.5MG		N202331	001	Dec 20, 2011	Feb	CAHN
	+		EQ 40MG MEDOXOMIL;25MG		N202331	002	Dec 20, 2011	Feb	CAHN
		<u>BACITRACIN</u>							
		OINTMENT;OPHTHALMIC							
		BACITRACIN							
	+	PERRIGO CO TENNESSEE	500 UNITS/GM		A061212	001		Feb	CTEC
		<u>BENDROFLUMETHIAZIDE; NADOLOL</u>							
		TABLET;ORAL							
		NADOLOL AND BENDROFLUMETHIAZIDE							
AB		MYLAN	5MG;40MG		A078688	001	Feb 15, 2008	Jan	CTNA
AB			5MG;80MG		A078688	002	Feb 15, 2008	Jan	CTNA
		<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE</u>							
		GEL;TOPICAL							
		BENZACLIN							
AB	+	VALEANT BERMUDA	5%;EQ 1% BASE		N050756	001	Dec 21, 2000	Mar	CRLD
	+		5%;EQ 1% BASE		N050756	002	Apr 20, 2007	Mar	CTEC
		<u>BEPOTASTINE BESILATE</u>							
		SOLUTION/DROPS;OPHTHALMIC							
		BEPREVE							
>A>	+	BAUSCH AND LOMB INC	1.5%		N022288	001	Sep 08, 2009	Apr	CAHN
>D>	+	ISTA PHARMS INC	1.5%		N022288	001	Sep 08, 2009	Apr	CAHN
		<u>BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE</u>							
		LOTION;TOPICAL							
		LOTRISONE							
AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%		N020010	001	Dec 08, 2000	Jan	CAHN
		<u>BETHANECHOL CHLORIDE</u>							
		TABLET;ORAL							
		DUVOID							
	@	WELLSPRING PHARM	10MG		A086262	001		Mar	DISC
	@		25MG		A086263	001		Mar	DISC
	@		50MG		A085882	003		Mar	DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE;ORAL
PYLERA

>A>	+	FOREST LABS INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Apr CAHN
>D>	+	FOREST RES INST INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Apr CAHN
	+		140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar CAHN

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMDAY

>A>	AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr CAHN
>D>	AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr CAHN
	AT	+		EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan CFTG

BROMFENAC SODIUM

	AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan CTEC
	AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan NEWA
	AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan CTEC

XIBROM

>A>		@	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr CAHN
>D>		@	ISTA PHARMS INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr CAHN

BUDESONIDECAPSULE;ORAL
BUDESONIDE

	AB		BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar NEWA
--	----	--	--------------------	-----	---------	-----	--------------	----------

SPRAY, METERED;NASAL

>A>			BUDESONIDE					
>A>	AB		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Apr NEWA
			RHINOCORT					

>D>		+	ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999	Apr CFTG
>A>		+		0.032MG/INH	N020746	001	Oct 01, 1999	Apr CFTG

TABLET, EXTENDED RELEASE;ORAL
UCERIS

		+	SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Feb CAHN
		+	SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar CAHN

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

	AB3		ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan NEWA
--	-----	--	----------------------	-------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

	AB		ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan NEWA
	AB			10MG	A078888	002	Feb 07, 2014	Jan NEWA
	AB			15MG	A078888	003	Feb 07, 2014	Jan NEWA
	AB			30MG	A078888	004	Feb 07, 2014	Jan NEWA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

	AP		EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006	Feb CAHN
--	----	--	----------------------	------------------------------------	---------	-----	--------------	----------

SOLUTION;ORAL

CAFFEINE CITRATE

	AA		EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Feb CAHN
--	----	--	----------------------	------------------------------------	---------	-----	--------------	----------

CALCIPOTRIENE

SOLUTION;TOPICAL

CALCIPOTRIENE

>D>	AT		TOLMAR	0.005%	A077029	001	Nov 20, 2009	Apr CRLD
>A>	AT	+		0.005%	A077029	001	Nov 20, 2009	Apr CRLD
>D>			DOVONEX					
>D>	AT	+	LEO PHARM	0.005%	N020611	001	Mar 03, 1997	Apr DISC
>A>		@		0.005%	N020611	001	Mar 03, 1997	Apr DISC

CALCITRIOLINJECTABLE; INJECTION
CALCITRIOL

@ TEVA PARENTERAL	0.002MG/ML	A075823	002	Mar 31, 2003	Feb DISC
-------------------	------------	---------	-----	--------------	----------

CAPTOPRILTABLET; ORAL
CAPTOPRIL

@ WATSON LABS	12.5MG	A074451	001	Feb 13, 1996	Mar DISC
@	25MG	A074451	002	Feb 13, 1996	Mar DISC
@	50MG	A074451	003	Feb 13, 1996	Mar DISC
@	100MG	A074451	004	Feb 13, 1996	Mar DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

@ APOTHECON	25MG;15MG	N018709	001	Oct 12, 1984	Mar DISC
-------------	-----------	---------	-----	--------------	----------

CAPOZIDE 25/25

@ APOTHECON	25MG;25MG	N018709	002	Oct 12, 1984	Mar DISC
-------------	-----------	---------	-----	--------------	----------

CAPOZIDE 50/15

@ APOTHECON	50MG;15MG	N018709	004	Oct 12, 1984	Mar DISC
-------------	-----------	---------	-----	--------------	----------

CAPOZIDE 50/25

@ APOTHECON	50MG;25MG	N018709	003	Oct 12, 1984	Mar DISC
-------------	-----------	---------	-----	--------------	----------

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB + MYLAN	25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD
------------	-----------	---------	-----	--------------	----------

AB +	50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD
------	-----------	---------	-----	--------------	----------

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb NEWA
------------------------	------	---------	-----	--------------	----------

LODOSYN

AB + ATON	25MG	N017830	001		Feb CFTG
-----------	------	---------	-----	--	----------

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

AA VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN
-------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

CARBINOXAMINE MALEATE

AA VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN
-------------------	-----	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP + PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN
----------------------	--------------------	---------	-----	--------------	----------

AP +	150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN
------	----------------------	---------	-----	--------------	----------

AP +	450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN
------	----------------------	---------	-----	--------------	----------

AP +	600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN
------	----------------------	---------	-----	--------------	----------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA
-----------------------	-------	---------	-----	--------------	----------

CEFACLOR

FOR SUSPENSION; ORAL

CEFACLOR

AB + YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan CRLD
----------------------	-------------------	---------	-----	--------------	----------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

@ ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan CAHN
------------------	-------------------	---------	-----	--------------	----------

@	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan CAHN
---	-------------------	---------	-----	--------------	----------

@	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan CAHN
---	-------------------	---------	-----	--------------	----------

@	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan CAHN
---	-------------------	---------	-----	--------------	----------

@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan CAHN
---	-------------------	---------	-----	--------------	----------

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

	@ STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar	DISC
--	----------------	------------------	---------	-----	--------------	-----	------

CEFTAZIDIME SODIUMINJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

>A>	@ COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr	CAHN
>A>	+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr	CAHN
>A>	+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr	CAHN
>D>	@ COVIS PHARMA	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr	CAHN
>D>	+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr	CAHN
>D>	+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr	CAHN

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
CEFTRIAXONE

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb	CAHN
>A>	SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014	Apr	NEWA

CEFUROXIME SODIUMINJECTABLE; IM-IV
ZINACEF

>A>	AB	+ COVIS INJECTABLES	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Apr	CAHN
>D>	AB	+ COVIS PHARMA	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Apr	CAHN
		INJECTABLE; INJECTION						
		ZINACEF						
>A>	AP	+ COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr	CAHN
>A>	AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr	CAHN
>D>	AP	+ COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr	CAHN
>D>	AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr	CAHN

CEPHALEXINCAPSULE; ORAL
CEPHALEXIN

	@ STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar	DISC
--	-------------	---------------	---------	-----	--------------	-----	------

>A>		<u>CERITINIB</u>						
>A>		CAPSULE; ORAL						
>A>		ZYKADIA						
>A>	+	NOVARTIS PHARMS CORP	150MG	N205755	001	Apr 29, 2014	Apr	NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

>A>		HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
>A>	AA	PADDOCK LLC	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Apr	NEWA
		ZUTRIPRO						
>D>	+	CYPRESS PHARM	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr	CFTG
>A>	AA	+	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr	CFTG

CHLORPROPAMIDETABLET; ORAL
CHLORPROPAMIDE

	@ ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984	Jan	CAHN	
	@	100MG	A088812	001	Oct 19, 1984	Jan	CAHN	
	@	100MG	A088840	001	Oct 25, 1984	Feb	CAHN	
	@	100MG	A088918	001	Oct 16, 1984	Jan	CAHN	
AB	@	100MG	A088921	001	Apr 12, 1985	Jan	CAHN	
	@	100MG	A089446	001	Nov 17, 1986	Jan	CAHN	
	@	250MG	A088813	001	Oct 19, 1984	Jan	CAHN	
	@	250MG	A088919	001	Oct 16, 1984	Jan	CAHN	
AB	@	250MG	A088922	001	Apr 12, 1985	Jan	CAHN	
	@	250MG	A089447	001	Nov 17, 1986	Jan	CAHN	
>D>	@	IVAX PHARMS	250MG	A087353	001		Apr	CAHN
>A>	@	TEVA PHARMS USA	250MG	A087353	001		Apr	CAHN
		GLUCAMIDE						
>D>	@	ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Apr	CAHN
	@	250MG	A088641	001	Oct 11, 1984	Jan	CAHN	
>A>	@	TEVA PHARMS USA	250MG	A088641	001	Oct 11, 1984	Apr	CAHN

CICLOPIROXCREAM; TOPICAL
CICLOPIROX

AB	TARO	0.77%	A076790	001	Apr 12, 2005	Mar	CMFD
	@	0.77%	A076790	001	Apr 12, 2005	Feb	DISC

CIMETIDINE HYDROCHLORIDESOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE

AA	ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN
	@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN
	@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN

CIPROFLOXACINFOR SUSPENSION; ORAL
CIPRO

AB	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
AB	+	500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG
	CIPROFLOXACIN						
AB	LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb	NEWA
AB		500MG/5ML	A200563	002	Mar 05, 2014	Feb	NEWA

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

>D>	AT	HITECH PHARMA	EQ 0.3% BASE	A076673	001	Jan 21, 2005	Apr	CAHN
>A>	AT	WATSON LABS INC	EQ 0.3% BASE	A076673	001	Jan 21, 2005	Apr	CAHN

CISPLATININJECTABLE; INJECTION
CISPLATIN

AP	PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb	CAHN
----	-----------------	--------	---------	-----	--------------	-----	------

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb	NEWA
----	---------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATESOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

>D>		@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Apr	CMFD
>A>	AB		EQ 1% BASE	A062811	001	Sep 01, 1988	Apr	CMFD
		@ VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb	CAHN

CLONIDINEFILM, EXTENDED RELEASE; TRANSDERMAL
CLONIDINE

>A>	AB	WATSON LABS INC	0.1MG/24HR	A090873	001	May 06, 2014	Apr	NEWA
>A>	AB		0.2MG/24HR	A090873	002	May 06, 2014	Apr	NEWA
>A>	AB		0.3MG/24HR	A090873	003	May 06, 2014	Apr	NEWA

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb	NEWA
AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
CLONIDINE HYDROCHLORIDE

AB	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar	NEWA
AB		0.2MG	A202983	002	Apr 02, 2014	Mar	NEWA

CLOPIDOGRELTABLET; ORAL
CLOPIDOGREL

AB	AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar	NEWA
----	---------------	------	---------	-----	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb	NEWA
AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan	NEWA

CLOZAPINE

TABLET; ORAL

CLOZAPINE

AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
AB		200MG	A076809	001	Dec 16, 2005	Mar	CTEC
AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar	NEWA
AB		50MG	A075417	004	Apr 15, 2010	Mar	NEWA
AB		200MG	A075417	005	Apr 15, 2010	Mar	NEWA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb	NEWA
	COLY-MYCIN M						
>D>	AP + JHP PHARMS	EQ 150MG BASE/VIAL	N050108	002		Apr	CAHN
>A>	AP + PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108	002		Apr	CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

>D>	+ JHP PHARMS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001		Apr	CAHN
>A>	+ PAR STERILE PRODUCTS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001		Apr	CAHN

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL

@ CUMBERLAND PHARMS 20MG/4ML (5MG/ML)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+ CUMBERLAND PHARMS 20MG/100ML (0.2MG/ML)

N021697	001	Dec 29, 2005	Feb	CAHN
N021697	002	Oct 08, 2008	Feb	CAHN

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

AB	PAR STERILE PRODUCTS	25MG	N017443	001		Mar	CAHN
AB		50MG	N017443	003		Mar	CAHN
AB	+	100MG	N017443	002		Mar	CAHN

INJECTABLE; INJECTION

DANTRIUM

>D>	AP + JHP PHARMS	20MG/VIAL	N018264	001		Apr	CAHN
>A>	AP + PAR STERILE PRODUCTS	20MG/VIAL	N018264	001		Apr	CAHN

REVONTO

AP	US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar	CTNA
----	--------------	-----------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN

TABLET; ORAL

FARXIGA

	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb	CAHN
+		10MG	N202293	002	Jan 08, 2014	Feb	CAHN
	BRISTOL MYERS SQUIBB	5MG	N202293	001	Jan 08, 2014	Jan	NEWA
+		10MG	N202293	002	Jan 08, 2014	Jan	NEWA

DECITABINE

POWDER; INTRAVENOUS

DECITABINE

+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Jan	NEWA
---	-------------------	-----------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

@ ANI PHARMS INC 25MG

@ 50MG

@ 75MG

@ 100MG

A071800	001	Dec 08, 1987	Jan	CAHN
A071801	001	Dec 08, 1987	Jan	CAHN
A071802	001	Dec 08, 1987	Jan	CAHN
A071803	001	May 29, 1997	Feb	CAHN

	TABLET;ORAL								
	DESIPRAMINE HYDROCHLORIDE								
	@	150MG	A071804	001	May 29, 1997	Feb	CAHN		
	<u>DESMOPRESSIN ACETATE</u>								
	SPRAY, METERED;NASAL								
	DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)								
AB	SUN PHARMA GLOBAL	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Jan	CMS2		
	<u>DESOXIMETASONE</u>								
	OINTMENT;TOPICAL								
	DESOXIMETASONE								
>A> AB	VERSAPHARM INC	0.25%	A201005	001	Apr 24, 2014	Apr	NEWA		
	<u>DESVENLAFAXINE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	DESVENLAFAXINE								
BC	SUN PHARMA GLOBAL	50MG	N205583	001	Jan 28, 2014	Jan	NEWA		
BC	+	100MG	N205583	002	Jan 28, 2014	Jan	NEWA		
	<u>DESVENLAFAXINE FUMARATE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	DESVENLAFAXINE FUMARATE								
	+	SUN PHARMA GLOBAL EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb	CTEC		
	+	EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb	CTEC		
	<u>DEXCHLORPHENIRAMINE MALEATE</u>								
	TABLET;ORAL								
	DEXCHLORPHENIRAMINE MALEATE								
	@ ANI PHARMS INC	2MG	A088682	001	Jan 17, 1986	Jan	CAHN		
	<u>DEXTROAMPHETAMINE SULFATE</u>								
	TABLET;ORAL								
	DEXTROAMPHETAMINE SULFATE								
AA	COREPHARMA	5MG	A090652	001	Mar 07, 2014	Feb	NEWA		
AA		10MG	A090652	002	Mar 07, 2014	Feb	NEWA		
	<u>DIAZEPAM</u>								
	CONCENTRATE;ORAL								
	DIAZEPAM								
AA	LANNETT HOLDINGS INC	5MG/ML	A204433	001	Apr 14, 2014	Mar	NEWA		
	DIAZEPAM INTENSOL								
AA	+	ROXANE 5MG/ML	A071415	001	Apr 03, 1987	Mar	CFTG		
	TABLET;ORAL								
	DIAZEPAM								
	@ DAVA PHARMS INC	2MG	A070226	001	Sep 26, 1985	Mar	DISC		
	<u>DICLOFENAC POTASSIUM</u>								
	FOR SOLUTION;ORAL								
	CAMBIA								
	+	DEPOMED INC 50MG	N022165	001	Jun 17, 2009	Jan	CAHN		
	<u>DICLOFENAC SODIUM</u>								
	SOLUTION;TOPICAL								
	PENNSAID								
	+	MALLINCKRODT INC 2%	N204623	001	Jan 16, 2014	Jan	NEWA		
	<u>DICLOFENAC SODIUM; MISOPROSTOL</u>								
	TABLET, DELAYED RELEASE;ORAL								
	DICLOFENAC SODIUM AND MISOPROSTOL								
AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar	NEWA		
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar	NEWA		
	<u>DICYCLOMINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	BENTYL								
>D> AB	+	APTALIS PHARMA US 10MG	N007409	003	Oct 15, 1984	Apr	CAHN		
>A> AB	+	FOREST LABS INC 10MG	N007409	003	Oct 15, 1984	Apr	CAHN		
	INJECTABLE;INJECTION								
	BENTYL								
>D> AP	+	APTALIS PHARMA US 10MG/ML	N008370	001	Oct 15, 1984	Apr	CAHN		

INJECTABLE; INJECTION									
BENTYL									
>A>	AP	+	FOREST LABS INC	10MG/ML	N008370	001	Oct 15, 1984	Apr	CAHN
BENTYL PRESERVATIVE FREE									
>D>	AP	+	APTALIS PHARMA US	10MG/ML	N008370	002	Oct 15, 1984	Apr	CAHN
>A>	AP	+	FOREST LABS INC	10MG/ML	N008370	002	Oct 15, 1984	Apr	CAHN
TABLET; ORAL									
BENTYL									
>D>	AB	+	APTALIS PHARMA US	20MG	N007409	001	Oct 15, 1984	Apr	CAHN
>A>	AB	+	FOREST LABS INC	20MG	N007409	001	Oct 15, 1984	Apr	CAHN
<u>DIGOXIN</u>									
INJECTABLE; INJECTION									
LANOXIN									
>A>	AP	+	COVIS INJECTABLES	0.25MG/ML	N009330	002		Apr	CAHN
>D>	AP	+	COVIS PHARMA	0.25MG/ML	N009330	002		Apr	CAHN
LANOXIN PEDIATRIC									
>A>		+	COVIS INJECTABLES	0.1MG/ML	N009330	004		Apr	CAHN
>D>		+	COVIS PHARMA	0.1MG/ML	N009330	004		Apr	CAHN
TABLET; ORAL									
LANOXIN									
			COVIS PHARMA	0.0625MG	N020405	001	Sep 30, 1997	Jan	CMFD
				0.1875MG	N020405	003	Sep 30, 1997	Jan	CMFD
<u>DILTIAZEM HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
DILTIAZEM HYDROCHLORIDE									
		@	NESHER PHARMS	120MG	A076563	002	Sep 12, 2006	Mar	DISC
		@		180MG	A076563	003	Sep 12, 2006	Mar	DISC
		@		240MG	A076563	004	Sep 12, 2006	Mar	DISC
		@		300MG	A076563	005	Sep 12, 2006	Mar	DISC
		@		360MG	A076563	006	Sep 12, 2006	Mar	DISC
		@		420MG	A076563	001	Sep 12, 2006	Mar	DISC
INJECTABLE; INJECTION									
DILTIAZEM HYDROCHLORIDE									
		@	AGILA SPECLTS	5MG/ML	A075375	001	Sep 30, 1999	Feb	CAHN
<u>DIPYRIDAMOLE</u>									
TABLET; ORAL									
DIPYRIDAMOLE									
		@	GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991	Mar	DISC
		@		50MG	A089000	001	Feb 05, 1991	Mar	DISC
		@		75MG	A089001	001	Feb 05, 1991	Mar	DISC
<u>DISULFIRAM</u>									
TABLET; ORAL									
DISULFIRAM									
AB			ROXANE	250MG	A202652	001	Feb 05, 2014	Jan	NEWA
AB				500MG	A202652	002	Feb 05, 2014	Jan	NEWA
<u>DOCETAXEL</u>									
INJECTABLE; INJECTION									
DOCETAXEL									
			PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Mar	NEWA
				80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Mar	NEWA
				130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Mar	NEWA
				200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Mar	NEWA
<u>DONEPEZIL HYDROCHLORIDE</u>									
TABLET; ORAL									
DONEPEZIL HYDROCHLORIDE									
AB			MACLEODS PHARMS LTD	23MG	A202631	001	Jan 22, 2014	Jan	NEWA
<u>DOXERCALCIFEROL</u>									
INJECTABLE; INJECTION									
DOXERCALCIFEROL									
>A>	AP		SANDOZ	4MCG/2ML (2MCG/ML)	A091333	001	May 05, 2014	Apr	NEWA
	AP			4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan	NEWA

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP	PHARMACHEMIE BV	2MG/ML	A 063336	001	Feb 28, 1995	Feb	CAHN
AP		10MG/VIAL	A 063097	001	May 21, 1990	Feb	CAHN
AP		20MG/VIAL	A 063097	002	May 21, 1990	Feb	CAHN
AP		50MG/VIAL	A 063097	003	May 21, 1990	Feb	CAHN
AP		200MG/100ML	A 063336	004	Feb 28, 1995	Feb	CAHN

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

AB	LUPIN LTD	EQ 50MG BASE	A 204234	001	Mar 05, 2014	Feb	NEWA
AB		EQ 75MG BASE	A 204234	002	Mar 05, 2014	Feb	NEWA
AB		EQ 100MG BASE	A 204234	003	Mar 05, 2014	Feb	NEWA

DOXYCYCLINE HYCLATETABLET, DELAYED RELEASE; ORAL
DORYX

AB	MAYNE PHARMA	EQ 150MG BASE	N 050795	003	Jun 20, 2008	Feb	CRLD
	+	EQ 200MG BASE	N 050795	005	Apr 11, 2013	Feb	CRLD

DROXIDOPACAPSULE; ORAL
NORTHERA

	CHELSEA THERAPS INC	100MG	N 203202	001	Feb 18, 2014	Feb	NEWA
		200MG	N 203202	002	Feb 18, 2014	Feb	NEWA
	+	300MG	N 203202	003	Feb 18, 2014	Feb	NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDECAPSULE; ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ANCHEN PHARMS	0.5MG; 0.4MG	A 202509	001	Feb 26, 2014	Feb	NEWA	
	JALYN							
AB	+	GLAXOSMITHKLINE	0.5MG; 0.4MG	N 022460	001	Jun 14, 2010	Feb	CFTG

ECONAZOLE NITRATEAEROSOL, FOAM; TOPICAL
ECOZA

	+	VELDANA MEDICAL SA	1%	N 205175	001	Oct 24, 2013	Feb	CAHN
--	---	--------------------	----	----------	-----	--------------	-----	------

CREAM; TOPICAL
SPECTAZOLE

	@	MERZ PHARMS LLC	1%	N 018751	001	Dec 23, 1982	Jan	CAHN
--	---	-----------------	----	----------	-----	--------------	-----	------

EPINEPHRINEINJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

>D>	+	JHP PHARMS	1MG/ML	N 204200	001	Dec 07, 2012	Apr	CAHN
>A>	+	PAR STERILE PRODUCTS	1MG/ML	N 204200	001	Dec 07, 2012	Apr	CAHN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

>D>	+	JHP PHARMS LLC	30MG/30ML (1MG/ML)	N 204640	001	Dec 18, 2013	Apr	CAHN
>A>	+	PAR STERILE PRODUCTS	30MG/30ML (1MG/ML)	N 204640	001	Dec 18, 2013	Apr	CAHN

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

	@	MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A 090266	001	Apr 15, 2011	Mar	DISC
	@		200MG/100ML (2MG/ML)	A 090266	002	Apr 15, 2011	Mar	DISC

ERYTHROMYCINTABLET, DELAYED RELEASE; ORAL
ERY-TAB

>D>	+	ARBOR PHARMS INC	250MG	A 062298	001		Apr	CRLD
>A>			250MG	A 062298	001		Apr	CRLD

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROMYCIN STEARATE

@ ANI PHARMS INC	EQ 250MG BASE	A 061461	001		Feb CAHN
@	EQ 250MG BASE	A 061591	001		Jan CAHN
@	EQ 500MG BASE	A 061461	002		Feb CAHN
@	EQ 500MG BASE	A 063179	001	May 15, 1990	Feb CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB	TEVA PHARMS USA	EQ 5MG BASE	A 076765	001	Mar 14, 2012	Feb CAHN
AB		EQ 10MG BASE	A 076765	002	Mar 14, 2012	Feb CAHN
AB		EQ 20MG BASE	A 076765	003	Mar 14, 2012	Feb CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM

>D>						
>D>	ASTRAZENECA LP	EQ 20MG BASE	N 204655	001	Mar 28, 2014	Apr CMS2
		EQ 20MG BASE	N 204655	001	Mar 28, 2014	Mar NEWA

ESTRADIOL

GEL;TRANSDERMAL

DIVIGEL

>D>	UPSHER SMITH	0.1% (0.25GM/PACKET)	N 022038	001	Jun 04, 2007	Apr CAHN
>D>		0.1% (0.5GM/PACKET)	N 022038	002	Jun 04, 2007	Apr CAHN
>D>	+	0.1% (1GM/PACKET)	N 022038	003	Jun 04, 2007	Apr CAHN
>A>	VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N 022038	001	Jun 04, 2007	Apr CAHN
>A>		0.1% (0.5GM/PACKET)	N 022038	002	Jun 04, 2007	Apr CAHN
>A>	+	0.1% (1GM/PACKET)	N 022038	003	Jun 04, 2007	Apr CAHN

ESTRADIOL VALERATE

INJECTABLE;INJECTION

DELESTROGEN

>D>	AO	+	JHP PHARMS	10MG/ML	N 009402	002		Apr CAHN
>D>	AO	+		20MG/ML	N 009402	004		Apr CAHN
>D>	AO	+		40MG/ML	N 009402	003		Apr CAHN
>A>	AO	+	PAR STERILE PRODUCTS	10MG/ML	N 009402	002		Apr CAHN
>A>	AO	+		20MG/ML	N 009402	004		Apr CAHN
>A>	AO	+		40MG/ML	N 009402	003		Apr CAHN

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	DR REDDYS LABS LTD	1MG	A 091024	001	Apr 15, 2014	Mar NEWA
AB		2MG	A 091024	002	Apr 15, 2014	Mar NEWA
AB		3MG	A 091024	003	Apr 15, 2014	Mar NEWA
AB	GLENMARK GENERICS	1MG	A 091166	001	Apr 15, 2014	Mar NEWA
AB		2MG	A 091166	002	Apr 15, 2014	Mar NEWA
AB		3MG	A 091166	003	Apr 15, 2014	Mar NEWA
AB	LUPIN LTD	1MG	A 091124	001	Sep 13, 2011	Mar CMFD
AB		2MG	A 091124	002	Sep 13, 2011	Mar CMFD
AB		3MG	A 091124	003	Sep 13, 2011	Mar CMFD
AB	ROXANE	1MG	A 091153	001	Apr 15, 2014	Mar NEWA
AB		2MG	A 091153	002	Apr 15, 2014	Mar NEWA
AB		3MG	A 091153	003	Apr 15, 2014	Mar NEWA
AB	TEVA	1MG	A 091169	001	May 23, 2011	Jan CMFD
AB		2MG	A 091169	002	May 23, 2011	Jan CMFD
AB		3MG	A 091169	003	May 23, 2011	Jan CMFD

ETHINYL ESTRADIOL; ETNOGESTREL

RING;VAGINAL

NUVARING

>D>	+	ORGANON USA INC	0.015MG;0.12MG	N 021187	001	Oct 03, 2001	Apr CPOT
>A>	+		0.015MG/24HR;0.12MG/24HR	N 021187	001	Oct 03, 2001	Apr CPOT

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28
 LEVONORGESTREL AND ETHINYL ESTRADIOL
 AB1 HAUPT PHARMA 0.02MG;0.1MG A201108 001 Feb 05, 2014 Jan NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL
 ORTHO EVRA
 AB + JANSSEN PHARMS 0.035MG/24HR;0.15MG/24HR N021180 001 Nov 20, 2001 Mar CFTG
 + 0.035MG/24HR;0.15MG/24HR N021180 001 Nov 20, 2001 Mar CPOT
 XULANE
 AB MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A200910 001 Apr 16, 2014 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE;ORAL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
 >A> AB FAMY CARE LTD 0.025MG;0.8MG A203371 001 Apr 23, 2014 Apr NEWA
 >D> + WARNER CHILCOTT 0.025MG;0.8MG N022573 001 Dec 22, 2010 Apr CFTG
 >A> AB + 0.025MG;0.8MG N022573 001 Dec 22, 2010 Apr CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21
 GILDESS 1.5/30
 AB VINTAGE PHARMS LLC 0.03MG;1.5MG A077075 002 Jul 24, 2012 Mar NEWA
 GILDESS 1/20
 AB VINTAGE PHARMS LLC 0.02MG;1MG A077077 002 Jul 24, 2012 Mar NEWA
 LARIN 1.5/30
 AB NOVAST LABS LTD 0.03MG;1.5MG A202996 001 Mar 20, 2014 Mar NEWA

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE
 >D> ETHIODOL
 >D> @ GUERBET 99% N009190 001 Apr CMFD
 >A> + 99% N009190 001 Apr CMFD
 >A> LIPIODOL
 >A> + GUERBET 99% N009190 001 Apr CTNA

ETODOLAC

CAPSULE;ORAL
 ETODOLAC
 @ ANI PHARMS INC 200MG A074899 001 Jul 08, 1997 Feb CAHN
 @ 200MG A075126 001 Sep 16, 1999 Jan CAHN
 @ 300MG A074899 002 Jul 08, 1997 Feb CAHN
 AB @ 300MG A075126 002 Sep 16, 1999 Jan CAHN

ETOMIDATE

INJECTABLE;INJECTION
 ETOMIDATE
 AP AGILA SPECLTS 2MG/ML A078289 001 Jan 02, 2009 Feb CAHN

ETOPOSIDE

INJECTABLE;INJECTION
 ETOPOSIDE
 @ PHARMACHEMIE BV 20MG/ML A074227 001 Feb 22, 1996 Feb CAHN

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS
 BYETTA
 + ASTRAZENECA AB 300MCG/1.2ML (250MCG/ML) N021773 001 Apr 28, 2005 Mar CAHN
 + 600MCG/2.4ML (250MCG/ML) N021773 002 Apr 28, 2005 Mar CAHN

FAMOTIDINE

INJECTABLE;INJECTION
 FAMOTIDINE PRESERVATIVE FREE
 AP BEDFORD LABS 10MG/ML A075825 001 Apr 17, 2001 Feb CAHN

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

>D>	AB	NOVEN	100MCG/HR	A077775	004	Oct 16, 2009	Apr	DISC
>A>		@	100MCG/HR	A077775	004	Oct 16, 2009	Apr	DISC

FENTANYL-25

>D>	AB	NOVEN	25MCG/HR	A077775	001	Oct 16, 2009	Apr	DISC
>A>		@	25MCG/HR	A077775	001	Oct 16, 2009	Apr	DISC

FENTANYL-50

>D>	AB	NOVEN	50MCG/HR	A077775	002	Oct 16, 2009	Apr	DISC
>A>		@	50MCG/HR	A077775	002	Oct 16, 2009	Apr	DISC

FENTANYL-75

>D>	AB	NOVEN	75MCG/HR	A077775	003	Oct 16, 2009	Apr	DISC
>A>		@	75MCG/HR	A077775	003	Oct 16, 2009	Apr	DISC

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+	PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Mar	NEWA
---	-----------------	----------------------	---------	-----	--------------	-----	------

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Apr	DISC
>A>		@	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Apr	DISC
>D>	AP		400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Apr	DISC
>A>		@	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Apr	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan	NEWA	
AP	LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan	NEWA	
>A>	AP	UCSF RODIOPHARM	20-300mCi/ML	A203902	001	May 09, 2014	Apr	NEWA
	@	WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004	Feb	DISC
AP	WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014	Jan	NEWA	

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB	HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+	MEDA PHARMS INC	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar	CAHN
---	-----------------	------------------	---------	-----	--------------	-----	------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

>D>		@	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001		Apr	CMFD
>A>		+		0.025%;EQ 3.5MG BASE/GM	A060700	001		Apr	CMFD

FLUOCINONIDE

SOLUTION; TOPICAL

LIDEX

>D>		@	CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Apr	CMFD
>A>	AT			0.05%	N018849	001	Apr 06, 1984	Apr	CMFD

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL		FLUOXETINE HYDROCHLORIDE					
AB2	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Jan	CAHN
AB2		EQ 20MG BASE	A076287	002	May 20, 2008	Jan	CAHN
TABLET;ORAL		SARAFEM					
AB1	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jan	CFTG
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan	CFTG
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CFTG
		SELFEMRA					
AB1	TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Jan	NEWA
AB1		EQ 15MG BASE	A200151	002	Feb 03, 2014	Jan	NEWA
AB1		EQ 20MG BASE	A200151	003	Feb 03, 2014	Jan	NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR;ORAL		FLUPHENAZINE HYDROCHLORIDE					
	@ ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb	CAHN

FOLIC ACID

TABLET;ORAL		FOLIC ACID					
AA	CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL		FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE					
AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb	CAIN
AB	+	20MG;12.5MG	A079025	002	Sep 17, 2010	Feb	CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL		FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE						
AB	+	EMCURE PHARMS INDIA	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CRLD

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION		CEREBYX					
AP	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb	CMFD
		FOSPHENYTOIN SODIUM					
AP	AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb	CAHN

FUROSEMIDE

INJECTABLE;INJECTION		FUROSEMIDE					
AP	CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan	NEWA
TABLET;ORAL		FUROSEMIDE					
AB	CARACO	20MG	A091258	001	Apr 01, 2014	Mar	NEWA
AB		40MG	A091258	002	Apr 01, 2014	Mar	NEWA
AB		80MG	A091258	003	Apr 01, 2014	Mar	NEWA

GABAPENTIN

TABLET;ORAL		GABAPENTIN					
AB	ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb	CAHN
AB		800MG	A203244	001	Jul 12, 2013	Feb	CAHN

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS		COPAXONE						
	+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan	NEWA

GLYCOPYRROLATE

TABLET;ORAL		GLYCOPYRROLATE					
AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan	NEWA
AA		2MG	A091182	002	Feb 03, 2014	Jan	NEWA
AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb	CAHN

	TABLET;ORAL						
	GLYCOPYRROLATE						
AA		2MG	A090020	002	Oct 19, 2011	Feb	CAHN
	<u>GUANABENZ ACETATE</u>						
	TABLET;ORAL						
	GUANABENZ ACETATE						
	ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan	CAHN
	@	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar	CAHN
	+	EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan	CAHN
	@	EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar	CAHN
	<u>HALOBETASOL PROPIONATE</u>						
	OINTMENT;TOPICAL						
	HALOBETASOL PROPIONATE						
>D>	@ TARO	0.05%	A076994	001	Dec 16, 2004	Apr	CMFD
>A>	AB	0.05%	A076994	001	Dec 16, 2004	Apr	CMFD
	<u>HALOPERIDOL DECANOATE</u>						
	INJECTABLE;INJECTION						
	HALOPERIDOL DECANOATE						
AO	AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb	CMFD
AO		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb	CMFD
	<u>HEPARIN SODIUM</u>						
	INJECTABLE;INJECTION						
	HEPARIN SODIUM						
	+	FRESENIUS KABI USA 10,000 UNITS/ML	N017029	020	Mar 31, 2011	Mar	NEWA
	+	HOSPIRA 5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar	CRLD
	+	PFIZER 1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar	CRLD
	+	5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar	CRLD
	+	10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar	CRLD
	HEPARIN SODIUM IN PLASTIC CONTAINER						
	+	FRESENIUS KABI USA 1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar	CTEC
	+	10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar	CTEC
	+	20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar	CTEC
	HEPARIN SODIUM PRESERVATIVE FREE						
	+	FRESENIUS KABI USA 10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	NEWA
	+	HOSPIRA 10,000 UNITS/ML	A089522	001	May 04, 1987	Mar	CTEC
	+	PFIZER 1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar	CRLD
	<u>HYDROCHLOROTHIAZIDE</u>						
	CAPSULE;ORAL						
	HYDROCHLOROTHIAZIDE						
AB	CARACO	12.5MG	A090651	001	Apr 07, 2014	Mar	NEWA
	<u>HYDROCHLOROTHIAZIDE; IRBESARTAN</u>						
	TABLET;ORAL						
	IRBESARTAN AND HYDROCHLOROTHIAZIDE						
>A>	AB	PRINSTON INC 12.5MG;150MG	A203072	001	May 09, 2014	Apr	NEWA
>A>	AB	12.5MG;300MG	A203072	002	May 09, 2014	Apr	NEWA
	<u>HYDROCHLOROTHIAZIDE; METHYLDOPA</u>						
	TABLET;ORAL						
	METHYLDOPA AND HYDROCHLOROTHIAZIDE						
	MYLAN	15MG;250MG	A070265	002	Jan 23, 1986	Mar	CMS1
	<u>HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE</u>						
	TABLET;ORAL						
	MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
>A>	AB	HERITAGE PHARMS INC 12.5MG;7.5MG	A202150	001	Mar 07, 2014	Apr	CAHN
>A>	AB	12.5MG;15MG	A202150	002	Mar 07, 2014	Apr	CAHN
>A>	AB	25MG;15MG	A202150	003	Mar 07, 2014	Apr	CAHN
>D>	AB	INDICUS PHARMA 12.5MG;7.5MG	A202150	001	Mar 07, 2014	Apr	CAHN
	AB	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Feb	NEWA
>D>	AB	12.5MG;15MG	A202150	002	Mar 07, 2014	Apr	CAHN
	AB	12.5MG;15MG	A202150	002	Mar 07, 2014	Feb	NEWA
>D>	AB	25MG;15MG	A202150	003	Mar 07, 2014	Apr	CAHN
	AB	25MG;15MG	A202150	003	Mar 07, 2014	Feb	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
 AB MYLAN 25MG; 40MG

A070947 002 Mar 04, 1987 Mar CMS1

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT
 AB BOEHRINGER INGELHEIM 12.5MG; 40MG
 AB 12.5MG; 80MG
 AB + 25MG; 80MG

N021162 001 Nov 17, 2000 Feb CFTG
 N021162 002 Nov 17, 2000 Feb CFTG
 N021162 003 Apr 19, 2004 Feb CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE
 AB ALEMBIC PHARMS LTD 12.5MG; 40MG
 AB 12.5MG; 80MG
 AB 25MG; 80MG
 AB MYLAN PHARMS INC 12.5MG; 40MG
 AB 12.5MG; 80MG
 AB 25MG; 80MG
 AB TORRENT PHARMS LTD 12.5MG; 40MG
 AB 12.5MG; 80MG
 AB 25MG; 80MG

A203010 001 Feb 25, 2014 Feb NEWA
 A203010 002 Feb 25, 2014 Feb NEWA
 A203010 003 Feb 25, 2014 Feb NEWA
 A091648 001 Feb 25, 2014 Feb NEWA
 A091648 002 Feb 25, 2014 Feb NEWA
 A091648 003 Feb 25, 2014 Feb NEWA
 A201192 001 Feb 25, 2014 Feb NEWA
 A201192 002 Feb 25, 2014 Feb NEWA
 A201192 003 Feb 25, 2014 Feb NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

>A> HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE
 >A> AA PADDOCK LLC 5MG/5ML; 60MG/5ML
 REZIRA
 >D> + CYPRESS PHARM 5MG/5ML; 60MG/5ML
 >A> AA + 5MG/5ML; 60MG/5ML

A204658 001 Apr 29, 2014 Apr NEWA
 N022442 001 Jun 08, 2011 Apr CFTG
 N022442 001 Jun 08, 2011 Apr CFTG

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE
 @ TARO 1%

A086155 001 Mar DISC

LOTION; TOPICAL

ALA-CORT
 @ CROWN LABS 1%
 NUTRACORT
 @ DOW PHARM 1%

A083201 001 Mar DISC
 A080443 003 Mar DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%
 @ VINTAGE PHARMS 1%; 1%

A089440 001 May 17, 1988 Feb CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO
 >D> MALLINCKRODT INC 8MG
 >A> AB 8MG
 >D> 12MG
 >A> AB 12MG
 >D> 16MG
 >A> AB 16MG
 >A> HYDROMORPHONE HYDROCHLORIDE
 >A> AB ACTAVIS LABS FL INC 8MG
 >A> AB 12MG
 >A> AB 16MG

N021217 001 Mar 01, 2010 Apr CFTG
 N021217 001 Mar 01, 2010 Apr CFTG
 N021217 002 Mar 01, 2010 Apr CFTG
 N021217 002 Mar 01, 2010 Apr CFTG
 N021217 003 Mar 01, 2010 Apr CFTG
 N021217 003 Mar 01, 2010 Apr CFTG
 A202144 001 May 12, 2014 Apr NEWA
 A202144 002 May 12, 2014 Apr NEWA
 A202144 003 May 12, 2014 Apr NEWA

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA
 AP + ROCHE EQ 3MG BASE/3ML
 IBANDRONATE SODIUM
 AP SUN PHARM INDS LTD EQ 3MG BASE/3ML

N021858 001 Jan 06, 2006 Feb CFTG
 A090853 001 Feb 14, 2014 Feb NEWA

INDOMETHACIN

CAPSULE;ORAL

TIVORBEX

IROKO PHARMS LLC 20MG

N204768 001 Feb 24, 2014 Feb NEWA

+ 40MG

N204768 002 Feb 24, 2014 Feb NEWA

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

AB MYLAN PHARMS INC 75MG

A202139 001 Mar 20, 2014 Mar NEWA

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG FLEXTOUCH

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N020986 005 Oct 31, 2013 Feb NEWA

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXTOUCH

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N021536 005 Oct 31, 2013 Feb NEWA

IPRATROPIUM BROMIDE

SOLUTION;INHALATION

IPRATROPIUM BROMIDE

AN + MYLAN SPECLT 0.02%

A074755 001 Jan 10, 1997 Mar CAHN

ISOFLURANE

LIQUID;INHALATION

ISOFLURANE

AN PIRAMAL ENT 99.9%

A074502 001 Jun 27, 1995 Feb CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE;ORAL

DILATRATE-SR

>D> + ACTIENT PHARMS 40MG

N019790 001 Sep 02, 1988 Apr CAHN

>A> + AUXILIUM PHARMS LLC 40MG

N019790 001 Sep 02, 1988 Apr CAHN

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

AB ANI PHARMS INC 20MG

A075147 001 Nov 27, 1998 Jan CAHN

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

@ MIKAH PHARMA 2.5MG

A077169 001 Apr 24, 2006 Feb DISC

@ 5MG

A077169 002 Apr 24, 2006 Feb DISC

WATSON LABS 2.5MG

A077317 001 Jan 05, 2006 Feb CTEC

+ 5MG

A077317 002 Jan 05, 2006 Feb CTEC

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETALAR

>D> AP + JHP PHARMS EQ 10MG BASE/ML

N016812 001 Apr CAHN

>D> AP + EQ 50MG BASE/ML

N016812 002 Apr CAHN

>D> AP + EQ 100MG BASE/ML

N016812 003 Apr CAHN

>A> AP + PAR STERILE PRODUCTS EQ 10MG BASE/ML

N016812 001 Apr CAHN

>A> AP + EQ 50MG BASE/ML

N016812 002 Apr CAHN

>A> AP + EQ 100MG BASE/ML

N016812 003 Apr CAHN

KETOCONAZOLE

TABLET;ORAL

NIZORAL

AB + JANSSEN PHARMS 200MG

N018533 001 Mar CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ACUVAIL

AT + ALLERGAN 0.45%

N022427 001 Jul 22, 2009 Jan CFTG

KETOROLAC TROMETHAMINE

@ AKORN 0.45%

A203376 001 Feb 10, 2014 Feb DISC

AT 0.45%

A203376 001 Feb 10, 2014 Jan NEWA

LAMIVUDINE; ZIDOVUDINE

	TABLET; ORAL						
	LAMIVUDINE AND ZIDOVUDINE						
AB	HETERO LABS LTD V	150MG;300MG	A203259	001	Feb 03, 2014	Jan	NEWA

LANSOPRAZOLE

	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL						
	LANSOPRAZOLE						
	@ ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Jan	CAHN
	@	30MG	A078730	002	Oct 15, 2010	Jan	CAHN

LEVETIRACETAM

	TABLET; ORAL						
	LEVETIRACETAM						
AB	VINTAGE PHARMS	250MG	A077319	001	Mar 20, 2009	Feb	CAHN
AB		500MG	A077319	002	Mar 20, 2009	Feb	CAHN
AB		750MG	A077319	003	Mar 20, 2009	Feb	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	LEVETIRACETAM						
AB	VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Feb	CAHN
AB		750MG	A201464	002	May 25, 2012	Feb	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

	SOLUTION; ORAL						
	LEVOCETIRIZINE DIHYDROCHLORIDE						
AA	L PERRIGO CO	2.5MG/5ML	A091263	001	Nov 07, 2011	Jan	CAHN

LEVORPHANOL TARTRATE

	TABLET; ORAL						
	LEVORPHANOL TARTRATE						
	+ ROXANE	2MG	A074278	001	Mar 31, 2000	Feb	CRLD

LIDOCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	LIDOCAINE HYDROCHLORIDE							
AP	AGILA SPECLTS	2%	A202242	001	Apr 11, 2014	Mar	NEWA	
	LIDOPEN							
	@ MERIDIAN MEDCL TECHN	10%	N017549	001		Mar	DISC	
	XYLOCAINE PRESERVATIVE FREE							
	+ FRESENIUS KABI USA	10%	N016801	003		Mar	CTEC	
	JELLY; TOPICAL							
	ANESTACON							
	@ DSM PHARMS INC	2%	A080429	001		Jan	CAHN	
	GLYDO							
>A>	AT	SAGENT PHARMS	2%	A201094	001	Apr 28, 2014	Apr	NEWA
	SOLUTION; TOPICAL							
	LIDOCAINE HYDROCHLORIDE							
AT	IGI LABS INC	4%	A204494	001	Mar 12, 2014	Feb	NEWA	
	SYSTEM; INTRADERMAL							
	ZINGO							
	POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Mar	CMFD	

LIOTHYRONINE SODIUM

	INJECTABLE; INJECTION							
	TRIOSTAT							
>D>	AP	+ JHP PHARMS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Apr	CAHN
>A>	AP	+ PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Apr	CAHN

LOTEPREDNOL ETABONATE

	GEL; OPHTHALMIC						
	LOTEMAX						
	+ BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Feb	CAHN

LULICONAZOLE

	CREAM; TOPICAL						
	LUZU						
	+ MEDICIS	1%	N204153	001	Nov 14, 2013	Jan	CRLD

MALATHION

LOTION; TOPICAL
MALATHION

@ MYLAN PHARMS INC 0.5% A078743 001 Mar 06, 2009 Mar DISC

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
MEDROXYPROGESTERONE ACETATE

@ USL PHARMA 10MG A088484 001 Jul 26, 1984 Mar DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

@ INTL MEDICATION 10MG/ML A081309 001 Aug 30, 1993 Mar DISC

MERCAPTOPYRINE

>A> SUSPENSION; ORAL
>A> PURIXAN

>A> + NOVA LABS LTD 20MG/ML N205919 001 Apr 28, 2014 Apr NEWA

MESALAMINE

SUPPOSITORY; RECTAL
CANASA

>D> + APTALIS PHARMA US 1GM N021252 002 Nov 05, 2004 Apr CAHN

>D> @ 500MG N021252 001 Jan 05, 2001 Apr CAHN

>A> + FOREST LABS INC 1GM N021252 002 Nov 05, 2004 Apr CAHN

>A> @ 500MG N021252 001 Jan 05, 2001 Apr CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
GLUMETZA

+ SALIX PHARMS INC 1GM N021748 002 Jun 03, 2005 Feb CTEC

500MG N021748 001 Jun 03, 2005 Feb CTEC

+ SANTARUS INC 1GM N021748 002 Jun 03, 2005 Mar CAHN

500MG N021748 001 Jun 03, 2005 Mar CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB TEVA PHARMS USA 500MG; EQ 15MG BASE A091155 001 Mar 10, 2014 Feb NEWA

AB 850MG; EQ 15MG BASE A091155 002 Mar 10, 2014 Feb NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDAMET

>D> SB PHARMCO 1GM; EQ 2MG BASE N021410 004 Aug 25, 2003 Apr CFTG

>A> AB 1GM; EQ 2MG BASE N021410 004 Aug 25, 2003 Apr CFTG

>D> + 1GM; EQ 4MG BASE N021410 005 Aug 25, 2003 Apr CFTG

>A> AB + 1GM; EQ 4MG BASE N021410 005 Aug 25, 2003 Apr CFTG

>D> 500MG; EQ 2MG BASE N021410 002 Oct 10, 2002 Apr CFTG

>A> AB 500MG; EQ 2MG BASE N021410 002 Oct 10, 2002 Apr CFTG

>D> 500MG; EQ 4MG BASE N021410 003 Oct 10, 2002 Apr CFTG

>A> AB 500MG; EQ 4MG BASE N021410 003 Oct 10, 2002 Apr CFTG

>A> ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

>A> AB TEVA 1GM; EQ 4MG BASE A077337 004 May 07, 2014 Apr NEWA

>A> AB 1GM; EQ 2MG BASE A077337 003 May 07, 2014 Apr NEWA

>A> AB 500MG; EQ 2MG BASE A077337 001 May 07, 2014 Apr NEWA

>A> AB 500MG; EQ 4MG BASE A077337 002 May 07, 2014 Apr NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
KOMBIGLYZE XR

>A> ASTRAZENECA AB 1GM; EQ 2.5MG BASE N200678 003 Nov 05, 2010 Apr CAHN

>A> + 1GM; EQ 5MG BASE N200678 002 Nov 05, 2010 Apr CAHN

>A> 500MG; EQ 5MG BASE N200678 001 Nov 05, 2010 Apr CAHN

>D> BRISTOL MYERS SQUIBB 1GM; EQ 2.5MG BASE N200678 003 Nov 05, 2010 Apr CAHN

>D> + 1GM; EQ 5MG BASE N200678 002 Nov 05, 2010 Apr CAHN

>D> 500MG; EQ 5MG BASE N200678 001 Nov 05, 2010 Apr CAHN

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB		ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan	CAHN
AB			50MG	A040001	002	Jun 30, 1993	Jan	CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb	CAHN
AB			10MG	A202068	002	Mar 07, 2012	Feb	CAHN

METHOCARBAMOL

TABLET; ORAL

ROBAXIN

>D>	AA	+	ACTIENT PHARMS	500MG	N011011	004		Apr	CAHN
>A>	AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004		Apr	CAHN
			ROBAXIN-750						
>D>	AA	+	ACTIENT PHARMS	750MG	N011011	006		Apr	CAHN
>A>	AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Apr	CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

>D>		+	JHP PHARMS	2.5GM/VIAL	N011559	002		Apr	CAHN
>D>		@		5GM/VIAL	N011559	003		Apr	CAHN
>D>		+		200MG/VIAL	N011559	004	Dec 21, 2012	Apr	CAHN
>D>		+		500MG/VIAL	N011559	001		Apr	CAHN
>A>		+	PAR STERILE PRODUCTS	2.5GM/VIAL	N011559	002		Apr	CAHN
>A>		@		5GM/VIAL	N011559	003		Apr	CAHN
>A>		+		200MG/VIAL	N011559	004	Dec 21, 2012	Apr	CAHN
>A>		+		500MG/VIAL	N011559	001		Apr	CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA		VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb	CAHN
AA			5MG	A040624	002	Dec 28, 2006	Feb	CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>A>	AB		MYLAN	250MG	A070076	002	Apr 18, 1985	Apr	CMS1
-----	----	--	-------	-------	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP		+	EDISON THERAPS LLC	0.2MG/ML	N006035	004		Feb	CAHN
----	--	---	--------------------	----------	---------	-----	--	-----	------

TABLET; ORAL

METHERGINE

AB		+	EDISON THERAPS LLC	0.2MG	N006035	003		Feb	CAHN
----	--	---	--------------------	-------	---------	-----	--	-----	------

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB			COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb	NEWA
AB				10MG	A091159	002	Mar 12, 2014	Feb	NEWA
AB				20MG	A091159	003	Mar 12, 2014	Feb	NEWA

METRONIDAZOLE

GEL; VAGINAL

METRONIDAZOLE

VALEANT PHARM NORTH 1.3%

N205223	001	Mar 24, 2014	Mar	NEWA
---------	-----	--------------	-----	------

TABLET; ORAL

METRONIDAZOLE

AB			UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan	NEWA
AB				500MG	A203458	002	Jan 22, 2014	Jan	NEWA
>A>		@	VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	Apr	CAHN
>A>		@		500MG	A070039	001	Jan 29, 1985	Apr	CAHN
AB			WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar	CAHN
>D>		@	WORLD GEN	250MG	A070040	001	Jan 29, 1985	Apr	CAHN

	TABLET;ORAL							
	METRONIDAZOLE							
>D>	@	500MG		A 070039	001	Jan 29, 1985	Apr	CAHN
	<u>MICONAZOLE</u>							
	TABLET;BUCCAL							
	ORAVIG							
>A>	+	BIOALLIANCE PHARMA	50MG	N 022404	001	Apr 16, 2010	Apr	CAHN
>D>	+	VESTIQ PHARMS	50MG	N 022404	001	Apr 16, 2010	Apr	CAHN
	<u>MIDAZOLAM HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	MIDAZOLAM HYDROCHLORIDE							
>A>	AP	BEDFORD LABS	EQ 1MG BASE/ML	A 075421	002	Jun 20, 2000	Apr	CAHN
>A>	AP		EQ 5MG BASE/ML	A 075421	001	Jun 20, 2000	Apr	CAHN
>D>	AP	BEN VENUE	EQ 1MG BASE/ML	A 075421	002	Jun 20, 2000	Apr	CAHN
>D>	AP		EQ 5MG BASE/ML	A 075421	001	Jun 20, 2000	Apr	CAHN
	<u>MILTEFOSINE</u>							
	CAPSULE;ORAL							
	IMPAVIDO							
		PALADIN THERAP	50MG	N 204684	001	Mar 19, 2014	Mar	NEWA
	<u>MIVACURIUM CHLORIDE</u>							
	INJECTABLE; INJECTION							
	MIVACURIUM CHLORIDE							
	@	AGILA SPECLTS	EQ 2MG BASE/ML	A 078562	001	Apr 30, 2009	Feb	CAHN
	<u>MODAFINIL</u>							
	TABLET;ORAL							
	MODAFINIL							
AB		APOTEX INC	100MG	A 077667	001	Feb 03, 2014	Jan	NEWA
AB			200MG	A 077667	002	Feb 03, 2014	Jan	NEWA
	<u>MOMETASONE FUROATE</u>							
	AEROSOL, METERED; INHALATION							
>A>		ASMANEX HFA						
>A>		MERCK SHARP DOHME	0.10MG/INH	N 205641	001	Apr 25, 2014	Apr	NEWA
>A>	+		0.20MG/INH	N 205641	002	Apr 25, 2014	Apr	NEWA
	POWDER; INHALATION							
	ASMANEX TWISTHALER							
		MERCK SHARP DOHME	0.11MG/INH	N 021067	002	Feb 01, 2008	Mar	CAHN
	+		0.22MG/INH	N 021067	001	Mar 30, 2005	Mar	CAHN
	<u>MORPHINE SULFATE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	AVINZA							
AB2		KING PHARMS LLC	30MG	N 021260	001	Mar 20, 2002	Mar	CAHN
AB2			45MG	N 021260	005	Dec 18, 2008	Mar	CAHN
AB2			60MG	N 021260	002	Mar 20, 2002	Mar	CAHN
AB2			75MG	N 021260	006	Dec 18, 2008	Mar	CAHN
AB2			90MG	N 021260	003	Mar 20, 2002	Mar	CAHN
AB2	+		120MG	N 021260	004	Mar 20, 2002	Mar	CAHN
	SOLUTION;ORAL							
	MORPHINE SULFATE							
AA		CARACO	10MG/5ML	A 201011	001	Feb 05, 2014	Jan	NEWA
AA			20MG/5ML	A 201011	002	Feb 05, 2014	Jan	NEWA
	<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	EMBEDA							
		ALPHARMA PHARMS	20MG;0.8MG	N 022321	001	Aug 13, 2009	Mar	CAHN
			30MG;1.2MG	N 022321	002	Aug 13, 2009	Mar	CAHN
			50MG;2MG	N 022321	003	Aug 13, 2009	Mar	CAHN
	+		60MG;2.4MG	N 022321	004	Aug 13, 2009	Mar	CAHN
			80MG;3.2MG	N 022321	005	Aug 13, 2009	Mar	CAHN
			100MG;4MG	N 022321	006	Aug 13, 2009	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDE

TABLET; ORAL

AVELOX

AB	+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb CFTG
MOXIFLOXACIN HYDROCHLORIDE							
AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb NEWA
AB		DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb NEWA
AB		TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb NEWA
AB		TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP		AGILA SPECLTS	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Mar NEWA
AP			EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Mar NEWA
AP		ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011	Jan CPOT
AP			EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011	Jan CPOT
AP		ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Feb CAHN
AP			EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Feb CAHN
AP			EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014	Feb NEWA
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS							
>A>		EVZIO					
>A>	+	KALEO INC	0.4MG/0.4ML	N205787	001	Apr 03, 2014	Apr NEWA

NAPROXEN

TABLET; ORAL

NAPROXEN

@ DAVA PHARMS INC

@

@

250MG

375MG

500MG

A074410	001	Apr 28, 1995	Feb DISC
A074410	002	Apr 28, 1995	Feb DISC
A074410	003	Apr 28, 1995	Feb DISC

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB		APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan CAIN
AB			EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan CAIN
AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan CAIN

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

AB		STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan CAHN
TABLET, EXTENDED RELEASE; ORAL							
NEVIRAPINE							
AB		APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar NEWA
AB		SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar NEWA
VIRAMUNE XR							
AB	+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar CFTG

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB		LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar NEWA
AB			500MG	A090860	001	Mar 20, 2014	Mar NEWA
AB			750MG	A090892	001	Mar 20, 2014	Mar NEWA
>A>	AB	SUN PHARMA GLOBAL	1GM	A200484	002	Apr 23, 2014	Apr NEWA
>A>	AB		500MG	A200484	001	Apr 23, 2014	Apr NEWA
>A>	AB		750MG	A201273	001	Apr 23, 2014	Apr NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

>A>	AB	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	Apr CAHN
>A>	AB	+	30MG	N019488	002	Dec 21, 1988	Apr CAHN
>D>	AB	EKR THERAP	20MG	N019488	001	Dec 21, 1988	Apr CAHN
>D>	AB	+	30MG	N019488	002	Dec 21, 1988	Apr CAHN

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB	ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan	CAHN
AB		20MG	A074540	001	Oct 28, 1996	Jan	CAHN
AB		30MG	A074439	002	Dec 10, 1996	Jan	CAHN
AB		30MG	A074540	002	Oct 28, 1996	Jan	CAHN

CAPSULE, EXTENDED RELEASE;ORAL

CARDENE SR

>A>	+	CHIESI USA INC	30MG	N020005	001	Feb 21, 1992	Apr	CAHN
>A>		@	45MG	N020005	002	Feb 21, 1992	Apr	CAHN
>A>	+		60MG	N020005	003	Feb 21, 1992	Apr	CAHN
>D>	+	EKR THERAP	30MG	N020005	001	Feb 21, 1992	Apr	CAHN
>D>		@	45MG	N020005	002	Feb 21, 1992	Apr	CAHN
>D>	+		60MG	N020005	003	Feb 21, 1992	Apr	CAHN

INJECTABLE;INJECTION

CARDENE

>A>	AP	+	CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Apr	CAHN
>D>	AP	+	EKR THERAP	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Apr	CAHN

NICARDIPINE HYDROCHLORIDE

AP	LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan	CAHN
----	----------	----------------------	---------	-----	--------------	-----	------

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

>A>	+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CAHN
>D>	+	EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CAHN

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

>A>	+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CAHN
>D>	+	EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CAHN

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

>A>	+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008	Apr	CAHN
>D>	+	EKR THERAP	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008	Apr	CAHN

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

>A>	+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Apr	CAHN
>D>	+	EKR THERAP	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Apr	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB2	TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar	NEWA
AB2		60MG	A203126	002	Apr 03, 2014	Mar	NEWA
AB2		90MG	A203126	003	Apr 03, 2014	Mar	NEWA

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

NITROGLYCERIN

OINTMENT;INTRA-ANAL

RECTIV

>D>	+	APTALIS PHARMA	0.4%	N021359	001	Jun 21, 2011	Apr	CAHN
>A>	+	FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011	Apr	CAHN

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

	@	ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan	CAHN
AB			150MG	A075668	001	Sep 12, 2002	Jan	CAHN
	@		300MG	A075461	002	Jul 08, 2002	Jan	CAHN
AB			300MG	A075668	002	Sep 12, 2002	Jan	CAHN

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION;ORAL

>A>		AVENTYL							
>A>		RANBAXY	EQ 10MG BASE/5ML	N014685	001		Apr	CTNA	
>D>		AVENTYL HYDROCHLORIDE							
>D>	AA	+	RANBAXY	EQ 10MG BASE/5ML	N014685	001		Apr	DISC
>A>		@	EQ 10MG BASE/5ML	N014685	001			Apr	DISC
			NORTRIPTYLINE HYDROCHLORIDE						
>D>	AA		PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	Apr	CRLD
>A>	AA	+		EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	Apr	CRLD

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>A>	AB	AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014	Apr	NEWA
>A>	AB		10MG	A203708	002	May 15, 2014	Apr	NEWA
>A>	AB		15MG	A203708	003	May 15, 2014	Apr	NEWA
>A>	AB		20MG	A203708	004	May 15, 2014	Apr	NEWA
>A>	AB	MYLAN PHARMS INC	5MG	A202285	001	May 12, 2014	Apr	NEWA
>A>	AB		10MG	A202285	002	May 12, 2014	Apr	NEWA
>A>	AB		15MG	A202285	003	May 12, 2014	Apr	NEWA
>A>	AB		20MG	A202285	004	May 12, 2014	Apr	NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
LOVAZA

AB	+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar	CFTG
AB		TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar	NEWA
>A>		OMTRYG						
>A>	+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Apr	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID

AB		SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb	CAHN
AB	+		40MG;1.1GM	N021849	002	Feb 27, 2006	Feb	CAHN
			FOR SUSPENSION;ORAL					
			ZEGERID					
AB		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb	CAHN
AB	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

		@ LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Jan	DISC
			TABLET;ORAL					
			ONDANSETRON HYDROCHLORIDE					
AB		IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan	NEWA
AB			EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan	NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION
OXACILLIN SODIUM

		@ ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995	Feb	CAHN
		@	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995	Feb	CAHN
		@	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995	Feb	CAHN
		@	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995	Feb	CAHN
		@	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995	Feb	CAHN

OXALIPLATIN

INJECTABLE;IV (INFUSION)
OXALIPLATIN

AP		SUN PHARMA GLOBAL	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Mar	NEWA
AP			100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Mar	NEWA

OXANDROLONE

TABLET;ORAL
OXANDRIN

AB		CREALTA PHARMS LLC	2.5MG	N013718	001		Jan	CAHN
AB	+		10MG	N013718	002	Nov 05, 2001	Jan	CAHN

OXAZEPAMCAPSULE;ORAL
OXAZEPAM

>D>	AB	IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987	Apr	DISC
>A>		@	10MG	A070943	001	Aug 03, 1987	Apr	DISC
>D>	AB		15MG	A070944	001	Aug 03, 1987	Apr	DISC
>A>		@	15MG	A070944	001	Aug 03, 1987	Apr	DISC
>D>	AB		30MG	A070945	001	Aug 03, 1987	Apr	DISC
>A>		@	30MG	A070945	001	Aug 03, 1987	Apr	DISC

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

@ ANI PHARMS INC
@
@150MG
300MG
600MGA078005 001 Dec 11, 2007 Jan CAHN
A078005 002 Dec 11, 2007 Jan CAHN
A078005 003 Dec 11, 2007 Jan CAHNOXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNIN

AB BARR LABS DIV TEVA
OXYTROL3.9MG/24HR
3.9MG/24HRA090526 001 Mar 04, 2014 Feb NEWA
N021351 002 Feb 26, 2003 Feb CFTGOXYTOCIN

INJECTABLE;INJECTION

PITOCIN

>D> AP + JHP PHARMS

10USP UNITS/ML (10USP UNITS/ML)
100USP UNITS/10ML (10USP UNITS/ML)
500USP UNITS/50ML (10USP UNITS/ML)N018261 001
N018261 002 Jul 27, 2007 Apr CAHN
N018261 003 Sep 05, 2012 Apr CAHN

>A> AP + PAR STERILE PRODUCTS

10USP UNITS/ML (10USP UNITS/ML)
100USP UNITS/10ML (10USP UNITS/ML)
500USP UNITS/50ML (10USP UNITS/ML)N018261 001 Apr CAHN
N018261 002 Jul 27, 2007 Apr CAHN
N018261 003 Sep 05, 2012 Apr CAHN

>A>

SOLUTION;NASAL

SYNTOCINON

@ RETROPHIN INC

40USP UNITS/ML

N012285 001 Feb CAHN

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

@ MN PHARMS
@30MG/VIAL
90MG/VIALA078300 001 Mar 10, 2009 Jan DISC
A078300 002 Mar 10, 2009 Jan DISCPANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

ZENPEP

>D> APTALIS PHARMA US

218,000USP UNITS; 40,00USP UNITS;
136,000 USP UNITS
218,000USP UNITS; 40,00USP UNITS;
136,000 USP UNITSN022210 007 Mar 25, 2014 Apr CAHN
N022210 007 Mar 25, 2014 Mar NEWA>D> 16,000USP UNITS;3,000USP
UNITS;10,000USP UNITS

N022210 005 Jun 15, 2011 Apr CAHN

>D> 55,000USP UNITS;10,000USP
UNITS;34,000USP UNITS

N022210 002 Aug 27, 2009 Apr CAHN

>D> 82,000USP UNITS;15,000USP
UNITS;51,000USP UNITS

N022210 003 Aug 27, 2009 Apr CAHN

>D> 27,000USP UNITS;5,000USP
UNITS;17,000USP UNITS

N022210 001 Aug 27, 2009 Apr CAHN

>D> 109,000USP UNITS;20,000USP
UNITS;68,000USP UNITS

N022210 004 Aug 27, 2009 Apr CAHN

>D> + 136,000USP UNITS;25,000USP
UNITS;85,000USP UNITS

N022210 006 Jul 13, 2011 Apr CAHN

>A> FOREST LABS INC
218,000USP UNITS; 40,00USP UNITS;
136,000 USP UNITS

N022210 007 Mar 25, 2014 Apr CAHN

>A> 16,000USP UNITS;3,000USP
UNITS;10,000USP UNITS

N022210 005 Jun 15, 2011 Apr CAHN

>A> 55,000USP UNITS;10,000USP
UNITS;34,000USP UNITS

N022210 002 Aug 27, 2009 Apr CAHN

>A> 82,000USP UNITS;15,000USP
UNITS;51,000USP UNITS

N022210 003 Aug 27, 2009 Apr CAHN

>A> 27,000USP UNITS;5,000USP
UNITS;17,000USP UNITS

N022210 001 Aug 27, 2009 Apr CAHN

>A> 109,000USP UNITS;20,000USP
UNITS;68,000USP UNITS

N022210 004 Aug 27, 2009 Apr CAHN

CAPSULE, DELAYED RELEASE;ORAL
ZENPEP

>A>	+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011	Apr CAHN
TABLET;ORAL VIOKACE							
>A>		FOREST LABS INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Apr CAHN
>A>	+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Apr CAHN
>D>		FOREST RES INST INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Apr CAHN
>D>	+		39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar CAHN
>D>	+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Apr CAHN
	+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar CAHN

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

>A>	AB	PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014	Apr NEWA
-----	----	-----------------	--------------	---------	-----	--------------	----------

PARICALCITOLCAPSULE;ORAL
PARICALCITOL

AB		BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar NEWA
AB			2MCG	A202539	002	Mar 27, 2014	Mar NEWA
AB			4MCG	A202539	003	Mar 27, 2014	Mar NEWA

PAROXETINE HYDROCHLORIDECAPSULE;ORAL
PAXIL

	@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
	@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
	@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
	@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION;ORAL

PAXIL

AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN
----	---	---------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

PAXIL

AB		APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan CAHN
AB			EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan CAHN
AB			EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan CAHN
AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan CAHN
	@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

PAXIL CR

AB		APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB			EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

>D>	@	ACTIENT PHARMS	10MG	N018976	001	Dec 30, 1987	Apr CAHN
>D>	+		20MG	N018976	004	Jan 05, 1989	Apr CAHN
>A>	@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Apr CAHN
>A>	+		20MG	N018976	004	Jan 05, 1989	Apr CAHN

PENICILLIN G POTASSIUMINJECTABLE;INJECTION
PENICILLIN G POTASSIUM

AP		ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
AP			20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

AB	ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Jan	CAHN
AB		4MG	A078138	002	Nov 10, 2009	Jan	CAHN
AB		8MG	A078138	003	Nov 10, 2009	Jan	CAHN

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

>A>	@ ANI PHARMS INC	8MG	A089456	001	Sep 10, 1987	Apr	CAHN
>D>	@ IVAX PHARMS	2MG	A089707	001	Sep 10, 1987	Apr	CAHN
>D>	@	4MG	A089708	001	Sep 10, 1987	Apr	CAHN
>D>	@	8MG	A089456	001	Sep 10, 1987	Apr	CAHN
>D>	@	16MG	A089457	001	Sep 10, 1987	Apr	CAHN
>A>	@ TEVA PHARMS USA	2MG	A089707	001	Sep 10, 1987	Apr	CAHN
>A>	@	4MG	A089708	001	Sep 10, 1987	Apr	CAHN
>A>	@	16MG	A089457	001	Sep 10, 1987	Apr	CAHN

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

>A>	AA	ELITE LABS INC	35MG	A040762	001	Jan 28, 2008	Apr	CAHN
>D>	AA	MIKAH PHARMA	35MG	A040762	001	Jan 28, 2008	Apr	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Feb	NEWA
AA		30MG	A202858	002	Feb 14, 2014	Feb	NEWA
>A>	AA	30MG	A204414	001	May 05, 2014	Apr	NEWA
AA		37.5MG	A202846	001	Feb 05, 2014	Jan	NEWA

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

AA	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Jan	NEWA
----	----------------	--------	---------	-----	--------------	-----	------

PHENYTOIN

TABLET, CHEWABLE;ORAL

PHENYTOIN

>A>	AB	TARO	50MG	A200565	001	Apr 17, 2014	Apr	NEWA
-----	----	------	------	---------	-----	--------------	-----	------

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

>A>	@ ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003	Apr	CAHN
	@	100MG EXTENDED	A089441	001	Dec 18, 1986	Jan	CAHN
>D>	@ BARR	100MG EXTENDED	A040435	001	Jun 20, 2003	Apr	CAHN
	PROMPT PHENYTOIN SODIUM						
	@ ANI PHARMS INC	100MG PROMPT	A080259	001		Jan	CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

AB	MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb	CMFD
AB		10MG	A074063	002	Jan 27, 1994	Feb	CMFD
AB	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb	CTEC
AB	+	10MG	A074019	002	Sep 03, 1992	Feb	CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	LUPIN LTD	EQ 15MG BASE	A204133	001	Apr 07, 2014	Mar	NEWA
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Mar	NEWA
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Mar	NEWA

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb	CAHN
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb	CAHN
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb	CAHN

INJECTABLE; INJECTION
PIPERACILLIN

+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb CAHN
---	--	-------------------	---------	-----	--------------	----------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb CAHN
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb CAHN
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb CAHN
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSFOR SUSPENSION; ORAL
CO-LAV

@	VINTAGE PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A073428	001	Jan 28, 1992	Feb CAHN
---	----------------	--	---------	-----	--------------	----------

GO-EVAC

@	VINTAGE PHARMS	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A073433	001	Apr 28, 1992	Feb CAHN
---	----------------	--	---------	-----	--------------	----------

PORACTANT ALFASUSPENSION; INTRATRACHEAL
CUROSURF

>A>	+	CHIESI USA INC	80MG/ML	N020744	001	Nov 18, 1999	Apr CAHN
>D>	+	CORNERSTONE THERAP	80MG/ML	N020744	001	Nov 18, 1999	Apr CAHN

POSACONAZOLESOLUTION; IV (INFUSION)
NOXAFIL

+	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Mar NEWA
---	-------------------	------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDEINJECTABLE; INJECTION
POTASSIUM CHLORIDE

@	INTL MEDICATION	2MEQ/ML	A083163	001		Mar DISC
---	-----------------	---------	---------	-----	--	----------

PRAMIPEXOLE DIHYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
MIRAPEX ER

AB	+	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Jan CFTG
AB			0.75MG	N022421	002	Feb 19, 2010	Jan CFTG
AB			1.5MG	N022421	003	Feb 19, 2010	Jan CFTG
AB			2.25MG	N022421	006	Jun 17, 2011	Jan CFTG
AB			3MG	N022421	004	Feb 19, 2010	Jan CFTG
AB			3.75MG	N022421	007	Jun 17, 2011	Jan CFTG
AB			4.5MG	N022421	005	Feb 19, 2010	Jan CFTG

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan NEWA
AB			0.75MG	A202206	002	Feb 06, 2014	Jan NEWA
AB			1.5MG	A202206	003	Feb 06, 2014	Jan NEWA
AB			2.25MG	A202206	004	Feb 06, 2014	Jan NEWA
AB			3MG	A202206	005	Feb 06, 2014	Jan NEWA
AB			3.75MG	A202206	006	Feb 06, 2014	Jan NEWA
AB			4.5MG	A202206	007	Feb 06, 2014	Jan NEWA

PRAMLINTIDE ACETATEINJECTABLE; SUBCUTANEOUS
SYMLIN

		ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb CAHN
	+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb CAHN
	@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>D>	@ SANDOZ	10MG	A 076397	003	Oct 23, 2006	Apr	CMFD
>A>	AB	10MG	A 076397	003	Oct 23, 2006	Apr	CMFD
>D>	@	20MG	A 076397	002	Oct 23, 2006	Apr	CMFD
>A>	AB	20MG	A 076397	002	Oct 23, 2006	Apr	CMFD
>D>	@	40MG	A 076397	001	Oct 23, 2006	Apr	CMFD
>A>	AB	40MG	A 076397	001	Oct 23, 2006	Apr	CMFD

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	+	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A 074449	001	Dec 29, 1995	Feb	CRLD
		VASOCIDIN						
		@ NOVARTIS	EQ 0.23% PHOSPHATE;10%	N 018988	001	Aug 26, 1988	Feb	DISC

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE

AB	+	SANOFI AVENTIS US	EQ 15MG BASE	N 008316	001		Jan	CFTG
		PRIMAQUINE PHOSPHATE						
AB		ALVOGEN INC	EQ 15MG BASE	A 203924	001	Feb 03, 2014	Jan	NEWA
AB		BAYSHORE PHARMS LLC	EQ 15MG BASE	A 204476	001	Feb 25, 2014	Feb	NEWA

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

@ ANI PHARMS INC

1GM

A 040111 001 Dec 13, 1996 Jan CAHN

@

250MG

A 088958 001 Dec 02, 1985 Jan CAHN

@

500MG

A 088959 001 Dec 02, 1985 Jan CAHN

@

500MG

A 088974 001 Jul 22, 1985 Mar CAHN

@

750MG

A 089438 001 Mar 23, 1987 Jan CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL

PHENERGAN

>A>	@	DELCOR ASSET CORP	50MG	N 011689	001		Apr	CAHN
>D>	@	SHIONOGI INC	50MG	N 011689	001		Apr	CAHN

TABLET;ORAL

PHENERGAN

>A>	@	DELCOR ASSET CORP	12.5MG	N 007935	002		Apr	CAHN
>A>	@		25MG	N 007935	003		Apr	CAHN
>A>	@		50MG	N 007935	004		Apr	CAHN
>D>	@	WYETH PHARMS INC	12.5MG	N 007935	002		Apr	CAHN
>D>	@		25MG	N 007935	003		Apr	CAHN
>D>	@		50MG	N 007935	004		Apr	CAHN

PROMETHAZINE HYDROCHLORIDE

>A>	AB	SANDOZ	25MG	A 084176	003		Apr	CMS1
-----	----	--------	------	----------	-----	--	-----	------

PROPAFENONE HYDROCHLORIDE

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB		ANI PHARMS INC	150MG	A 076550	001	Apr 23, 2004	Jan	CAHN
AB			225MG	A 076550	002	Apr 23, 2004	Jan	CAHN
AB			300MG	A 076550	003	Apr 23, 2004	Jan	CAHN

PROPRANOLOL HYDROCHLORIDE

SOLUTION;ORAL

HEMANGEOL

+	PIERRE FABRE DERMA	4.28MG/ML	N 205410	001	Mar 14, 2014	Mar	NEWA
---	--------------------	-----------	----------	-----	--------------	-----	------

TABLET;ORAL

INDEFERAL

@ WYETH PHARMS INC

40MG

N 016418 002 Jan DISC

@

60MG

N 016418 009 Oct 18, 1982 Jan DISC

@

80MG

N 016418 004 Jan DISC

PROPRANOLOL HYDROCHLORIDE

@ ANI PHARMS INC

90MG

A 071977 001 Apr 06, 1988 Jan CAHN

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

@ ANI PHARMS INC

50MG

A080215 001

Jan CAHN

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA

AB + LILLY 60MG

N020815 001 Dec 09, 1997

Feb CFTG

RALOXIFENE HYDROCHLORIDE

AB TEVA PHARMS USA 60MG

A078193 001 Mar 04, 2014

Feb NEWA

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

AB ACCORD HLTHCARE INC 1.25MG

A202392 001 Apr 15, 2014 Mar NEWA

AB 2.5MG

A202392 002 Apr 15, 2014 Mar NEWA

AB 5MG

A202392 003 Apr 15, 2014 Mar NEWA

AB 10MG

A202392 004 Apr 15, 2014 Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

>A> AP + COVIS INJECTABLES EQ 25MG BASE/ML

N019090 001 Oct 19, 1984 Apr CAHN

>D> AP + COVIS PHARMA EQ 25MG BASE/ML

N019090 001 Oct 19, 1984 Apr CAHN

ZANTAC IN PLASTIC CONTAINER

>A> @ COVIS INJECTABLES EQ 1MG BASE/ML

N019593 002 Sep 27, 1991 Apr CAHN

>A> @ EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986 Apr CAHN

>D> @ COVIS PHARMA SARL EQ 1MG BASE/ML

N019593 002 Sep 27, 1991 Apr CAHN

>D> @ EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986 Apr CAHN

TABLET, EFFERVESCENT; ORAL

ZANTAC 25

@ GLAXO GRP LTD

EQ 25MG BASE

N020251 003 Apr 01, 2004

Feb DISC

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB ACTAVIS TOTOWA 0.5MG

A090008 001 Jan 22, 2014 Jan NEWA

AB 1MG

A090008 002 Jan 22, 2014 Jan NEWA

AB 2MG

A090008 003 Jan 22, 2014 Jan NEWA

AB AUROBINDO PHARMA LTD 0.5MG

A203820 001 Jan 22, 2014 Jan NEWA

AB 1MG

A203820 002 Jan 22, 2014 Jan NEWA

AB 2MG

A203820 003 Jan 22, 2014 Jan NEWA

AB MYLAN PHARMS INC 1MG

A090252 002 Jan 22, 2014 Jan NEWA

AB 2MG

A090252 003 Jan 22, 2014 Jan NEWA

AB PADDOCK LLC 1MG

A201189 002 Jan 22, 2014 Jan NEWA

AB 2MG

A201189 003 Jan 22, 2014 Jan NEWA

AB SANDOZ 1MG

A078555 002 Jan 22, 2014 Jan NEWA

AB 2MG

A078555 003 Jan 22, 2014 Jan NEWA

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN

AB + PHARMACIA AND UPJOHN 150MG

N050689 001 Dec 23, 1992 Feb CFTG

RIFABUTIN

AB LUPIN LTD 150MG

A090033 001 Feb 24, 2014 Feb NEWA

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

AA ANI PHARMS INC 1MG/ML

A076440 001 Jan 30, 2009 Jan CAHN

TABLET; ORAL

RISPERIDONE

AB CARACO 0.25MG

A078036 001 Mar 10, 2014 Feb NEWA

AB 0.5MG

A078036 002 Mar 10, 2014 Feb NEWA

AB 1MG

A078036 003 Mar 10, 2014 Feb NEWA

AB 2MG

A078036 004 Mar 10, 2014 Feb NEWA

AB 3MG

A078036 005 Mar 10, 2014 Feb NEWA

AB 4MG

A078036 006 Mar 10, 2014 Feb NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan NEWA
AB		EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan NEWA

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

+	JANSSEN RES AND DEV	EQ 150MG BASE	N205123	001	Nov 22, 2013	Feb CAIN
---	---------------------	---------------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP	UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014	Mar NEWA
----	-----------------	--------------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	EPIC PHARMA LLC	453.6GM/BOT	A202333	001	Mar 19, 2014	Mar NEWA
----	-----------------	-------------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	TEVA PHARMS USA	5MG	A091464	001	Apr 02, 2014	Mar NEWA
AB		10MG	A091464	002	Apr 02, 2014	Mar NEWA
	VESICARE					
AB	ASTELLAS	5MG	N021518	001	Nov 19, 2004	Mar CFTG
AB	+	10MG	N021518	002	Nov 19, 2004	Mar CFTG

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

ACCRETROPIN

@ EMERGENT 5MG/ML (5MG/ML)

N021538	001	Jan 23, 2008	Feb CAHN
---------	-----	--------------	----------

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

>A>	AB	JUBILANT LIFE	25MG	A203253	001	Apr 23, 2014	Apr NEWA
>A>	AB		50MG	A203253	002	Apr 23, 2014	Apr NEWA
>A>	AB		100MG	A203253	003	Apr 23, 2014	Apr NEWA
	AB	ORION CORP ORION	25MG	A202187	001	Mar 06, 2014	Feb NEWA
	AB		50MG	A202187	002	Mar 06, 2014	Feb NEWA
	AB		100MG	A202187	003	Mar 06, 2014	Feb NEWA

SUCRALFATE

SUSPENSION;ORAL

CARAFATE

>D>	+	APTALIS PHARMA US	1GM/10ML	N019183	001	Dec 16, 1993	Apr CAHN
>A>	+	FOREST LABS INC	1GM/10ML	N019183	001	Dec 16, 1993	Apr CAHN

TABLET;ORAL

CARAFATE

>D>	AB	+	APTALIS PHARMA US	1GM	N018333	001	Apr CAHN
>A>	AB	+	FOREST LABS INC	1GM	N018333	001	Apr CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP	AGILA SPECLTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Mar NEWA
AB	DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090495	001	Jan 29, 2014	Jan NEWA

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB	MYLAN PHARMS INC	EQ 12.5MG BASE	A201275	001	Jan 30, 2014	Jan NEWA
AB		EQ 25MG BASE	A201275	002	Jan 30, 2014	Jan NEWA
AB		EQ 37.5MG BASE	A201275	003	Jan 30, 2014	Jan NEWA
AB		EQ 50MG BASE	A201275	004	Jan 30, 2014	Jan NEWA

CAPSULE;ORAL
SUTENT

AB	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Jan CFTG
AB		EQ 25MG BASE	N021938	002	Jan 26, 2006	Jan CFTG
AB		EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Jan CFTG
AB	+	EQ 50MG BASE	N021938	003	Jan 26, 2006	Jan CFTG

TAFLUPROSTSOLUTION/DROPS;OPHTHALMIC
ZIOPTAN

>D>	+	MERCK SHARP DOHME	0.0015%	N202514	001	Feb 10, 2012	Apr CAHN
>A>	+	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Apr CAHN

TASIMELTEONCAPSULE;ORAL
HETLIOZ

+	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	Jan NEWA
---	------------------	------	---------	-----	--------------	----------

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

AB	SUN PHARMA GLOBAL	5MG	A201742	001	Feb 12, 2014	Feb NEWA
AB		20MG	A201742	002	Feb 12, 2014	Feb NEWA
AB		100MG	A201742	003	Feb 12, 2014	Feb NEWA
AB		140MG	A201742	004	Feb 12, 2014	Feb NEWA
AB		180MG	A201742	005	Feb 12, 2014	Feb NEWA
AB		250MG	A201742	006	Feb 12, 2014	Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

>D>		HYTRIN					
>D>	AB	ABBOTT	EQ 1MG BASE	N020347	001	Dec 14, 1994	Apr DISC
>A>		@	EQ 1MG BASE	N020347	001	Dec 14, 1994	Apr DISC
>D>	AB	+	EQ 2MG BASE	N020347	002	Dec 14, 1994	Apr DISC
>A>		@	EQ 2MG BASE	N020347	002	Dec 14, 1994	Apr DISC
>D>	AB		EQ 5MG BASE	N020347	003	Dec 14, 1994	Apr DISC
>A>		@	EQ 5MG BASE	N020347	003	Dec 14, 1994	Apr DISC
>D>	AB		EQ 10MG BASE	N020347	004	Dec 14, 1994	Apr DISC
>A>		@	EQ 10MG BASE	N020347	004	Dec 14, 1994	Apr DISC

TERAZOSIN HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 2MG BASE	A074823	002	Mar 30, 1998	Apr CRLD
>A>	AB	+	EQ 2MG BASE	A074823	002	Mar 30, 1998	Apr CRLD

TABLET;ORAL

>D>		HYTRIN					
>D>		ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987	Apr DISC
>A>		@	EQ 1MG BASE	N019057	001	Aug 07, 1987	Apr DISC
>D>		+	EQ 2MG BASE	N019057	002	Aug 07, 1987	Apr DISC
>A>		@	EQ 2MG BASE	N019057	002	Aug 07, 1987	Apr DISC
>D>			EQ 5MG BASE	N019057	003	Aug 07, 1987	Apr DISC
>A>		@	EQ 5MG BASE	N019057	003	Aug 07, 1987	Apr DISC
>D>			EQ 10MG BASE	N019057	004	Aug 07, 1987	Apr DISC
>A>		@	EQ 10MG BASE	N019057	004	Aug 07, 1987	Apr DISC

TESTOSTERONETABLET, EXTENDED RELEASE;BUCCAL
STRIANT

>D>	+	ACTIENT PHARMS	30MG	N021543	001	Jun 19, 2003	Apr CAHN
>A>	+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Apr CAHN

TESTOSTERONE UNDECANOATEINJECTABLE;INTRAMUSCULAR
AVEED

+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014	Mar NEWA
---	-----------------	----------------------	---------	-----	--------------	----------

THEOPHYLLINETABLET, EXTENDED RELEASE;ORAL
THEOCHRON

@	CARACO	300MG	A087400	002	Jan 11, 1983	Jan DISC
---	--------	-------	---------	-----	--------------	----------

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC 100MG/ML

A 089603 001 Nov 09, 1987 Feb CAHN

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC 10MG

A 088270 001 Apr 14, 1983 Feb CAHN

@ 10MG

A 088493 001 May 17, 1985 Feb CAHN

@ 15MG

A 088271 001 Apr 14, 1983 Feb CAHN

@ 25MG

A 088272 001 Apr 14, 1983 Feb CAHN

@ 50MG

A 088194 001 Apr 14, 1983 Feb CAHN

@ 100MG

A 088273 001 Oct 03, 1983 Feb CAHN

@ 100MG

A 088456 001 May 17, 1985 Feb CAHN

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

>A> + OAK PHARMS AKORN EQ 0.25% BASE

N 020439 001 Mar 31, 1995 Apr CAHN

>A> + EQ 0.5% BASE

N 020439 002 Mar 31, 1995 Apr CAHN

>D> + SANTEN OY EQ 0.25% BASE

N 020439 001 Mar 31, 1995 Apr CAHN

>D> + EQ 0.5% BASE

N 020439 002 Mar 31, 1995 Apr CAHN

TOBRAMYCIN

SOLUTION; INHALATION

BETHKIS

>A> CHIESI USA INC 300MG/4ML

N 201820 001 Oct 12, 2012 Apr CAHN

>D> CORNERSTONE THERAP 300MG/4ML

N 201820 001 Oct 12, 2012 Apr CAHN

TOPIRAMATE

>D> CAPSULE, DELAYED RELEASE; ORAL

>D> QUDEXY XR

>D> UPSHER SMITH 25MG

N 205122 001 Mar 11, 2014 Apr CDFR

25MG

N 205122 001 Mar 11, 2014 Mar NEWA

>D> 50MG

N 205122 002 Mar 11, 2014 Apr CDFR

50MG

N 205122 002 Mar 11, 2014 Mar NEWA

>D> 100MG

N 205122 003 Mar 11, 2014 Apr CDFR

100MG

N 205122 003 Mar 11, 2014 Mar NEWA

>D> 150MG

N 205122 004 Mar 11, 2014 Apr CDFR

150MG

N 205122 004 Mar 11, 2014 Mar NEWA

>D> + 200MG

N 205122 005 Mar 11, 2014 Apr CDFR

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> QUDEXY XR

>A> UPSHER SMITH 25MG

N 205122 001 Mar 11, 2014 Apr CDFR

>A> 50MG

N 205122 002 Mar 11, 2014 Apr CDFR

>A> 100MG

N 205122 003 Mar 11, 2014 Apr CDFR

>A> 150MG

N 205122 004 Mar 11, 2014 Apr CDFR

>A> + 200MG

N 205122 005 Mar 11, 2014 Apr CDFR

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

>A> AP INNOPHARMA LICENSING EQ 4MG BASE/VIAL

A 201166 001 Aug 08, 2012 Apr CAHN

>D> AP MYLAN INSTITUTIONAL EQ 4MG BASE/VIAL

A 201166 001 Aug 08, 2012 Apr CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>A> AB ALLIED PHARMA INC 50MG

A 202075 001 Nov 28, 2011 Apr CAHN

>D> AB ALVOGEN 50MG

A 202075 001 Nov 28, 2011 Apr CAHN

AB AUROBINDO PHARMA LTD 50MG

A 203494 001 Mar 31, 2014 Mar NEWA

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP ACIC FINE CHEMS 100MG/ML

A 202436 001 Feb 11, 2014 Jan NEWA

TABLET; ORAL

TRANEXAMIC ACID

AB APOTEX INC 650 MG

A 202286 001 Jan 27, 2014 Jan NEWA

TRAVOPROSTSOLUTION/DROPS;OPHTHALMIC
TRAVOPROST

+ PAR PHARM 0.004% A091340 001 Mar 01, 2013 Feb CRLD

TRETINOINGEL;TOPICAL
RETIN-A-MICRO

+ VALEANT INTL 0.08% N020475 003 Jan 28, 2014 Jan NEWA

SOLUTION;TOPICAL
RETIN-A

+ VALEANT INTL 0.05% N016921 001 Feb CTEC

TRETINOIN

@ WOCHKHARDT 0.05% A075260 001 Jan 25, 1999 Feb DISC

TRIAMCINOLONE ACETONIDELOTION;TOPICAL
TRIAMCINOLONE ACETONIDE

@ TARO 0.1% A089129 001 Aug 14, 1986 Mar DISC

>A> UMECLIDINIUM BROMIDE>A> POWDER;INHALATION
>A> INCRUSE ELLIPTA

>A> + GLAXO GRP ENGLAND EQ 62.5MCG BASE/INH N205382 001 Apr 30, 2014 Apr NEWA

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEPOWDER;INHALATION
ANORO ELLIPTA>D> + GLAXO GRP LTD EQ 0.0625MG BASE/INH;EQ 0.025MG N203975 001 Dec 18, 2013 Apr CAHN
BASE/INH>A> + GLAXOSMITHKLINE EQ 0.0625MG BASE/INH;EQ 0.025MG N203975 001 Dec 18, 2013 Apr CAHN
BASE/INHURSODIOLTABLET;ORAL
URSO 250

>D> AB APTALIS PHARMA US 250MG N020675 001 Dec 10, 1997 Apr CAHN

>A> AB FOREST LABS INC 250MG N020675 001 Dec 10, 1997 Apr CAHN

URSO FORTE

>D> AB + APTALIS PHARMA US 500MG N020675 002 Jul 21, 2004 Apr CAHN

>A> AB + FOREST LABS INC 500MG N020675 002 Jul 21, 2004 Apr CAHN

VALACYCLOVIR HYDROCHLORIDETABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

>D> AB ACTAVIS GRP PTC EQ 1GM BASE A090370 002 Mar 16, 2011 Apr CAHN

>D> AB EQ 500MG BASE A090370 001 Mar 16, 2011 Apr CAHN

AB APOTEX INC EQ 1GM BASE A090500 002 Apr 04, 2014 Mar NEWA

AB EQ 500MG BASE A090500 001 Apr 04, 2014 Mar NEWA

AB CIPLA LTD EQ 1GM BASE A077135 002 May 24, 2010 Jan CAHN

AB EQ 500MG BASE A077135 001 May 24, 2010 Jan CAHN

>A> AB WATSON LABS INC EQ 1GM BASE A090370 002 Mar 16, 2011 Apr CAHN

>A> AB EQ 500MG BASE A090370 001 Mar 16, 2011 Apr CAHN

VALPROIC ACIDSYRUP;ORAL
VALPROIC ACID

AA ANI PHARMS INC 250MG/5ML A073178 001 Aug 25, 1992 Jan CAHN

VANCOMYCIN HYDROCHLORIDEINJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

AP AGILA SPECLTS EQ 10GM BASE/VIAL A091554 001 Sep 19, 2011 Feb CAHN

>A> VASOPRESSIN

>A> SOLUTION;IV (INFUSION)

>A> VASOSTRICT

>A> + PAR STERILE PRODUCTS 20UNITS/ML (20UNITS/ML) N204485 001 Apr 17, 2014 Apr NEWA

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

>A>	AB	MYLAN	80MG	A071483	002	Feb 15, 1989	Apr	CMS1
-----	----	-------	------	---------	-----	--------------	-----	------

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

@ BRISTOL MYERS SQUIBB 5MG/VIAL

N009218	024	Feb 07, 1995	Mar	DISC
---------	-----	--------------	-----	------

TABLET; ORAL

COUMADIN

>D>		@ BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Apr	CMFD
>A>	AB		1MG	N009218	022	Mar 01, 1990	Apr	CMFD
		@	1MG	N009218	022	Mar 01, 1990	Mar	DISC
>D>		@	2MG	N009218	013		Apr	CMFD
>A>	AB		2MG	N009218	013		Apr	CMFD
		@	2MG	N009218	013		Mar	DISC
>D>		@	2.5MG	N009218	018		Apr	CMFD
>A>	AB		2.5MG	N009218	018		Apr	CMFD
		@	2.5MG	N009218	018		Mar	DISC
>D>		@	3MG	N009218	025	Nov 18, 1996	Apr	CMFD
>A>	AB		3MG	N009218	025	Nov 18, 1996	Apr	CMFD
		@	3MG	N009218	025	Nov 18, 1996	Mar	DISC
>D>		@	4MG	N009218	023	Aug 24, 1993	Apr	CMFD
>A>	AB		4MG	N009218	023	Aug 24, 1993	Apr	CMFD
		@	4MG	N009218	023	Aug 24, 1993	Mar	DISC
>D>	AB		5MG	N009218	007		Apr	CMFD
>A>	AB		5MG	N009218	007		Apr	CMFD
>D>		@	6MG	N009218	026	Nov 18, 1996	Apr	CMFD
>A>	AB		6MG	N009218	026	Nov 18, 1996	Apr	CMFD
		@	6MG	N009218	026	Nov 18, 1996	Mar	DISC
>D>		@	7.5MG	N009218	016		Apr	CMFD
>A>	AB		7.5MG	N009218	016		Apr	CMFD
		@	7.5MG	N009218	016		Mar	DISC
>D>	AB	+	10MG	N009218	005		Apr	CMFD
>A>	AB	+	10MG	N009218	005		Apr	CMFD

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

@ JAZZ PHARMS INTL 200MCG/2ML (100MCG/ML)

N021060	003	Dec 28, 2004	Feb	CAIN
---------	-----	--------------	-----	------

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

@ LIAONING CHENGDA 10MG/ML

A204538	001	Nov 26, 2013	Mar	DISC
---------	-----	--------------	-----	------

ZILEUTON

TABLET; ORAL

ZYFLO

>A>		@ CHIESI USA INC	300MG	N020471	001	Dec 09, 1996	Apr	CAHN
>A>	+		600MG	N020471	003	Dec 09, 1996	Apr	CAHN
>D>		@ CORNERSTONE THERAP	300MG	N020471	001	Dec 09, 1996	Apr	CAHN
>D>	+		600MG	N020471	003	Dec 09, 1996	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

ZYFLO CR

>A>	+	CHIESI USA INC	600MG	N022052	001	May 30, 2007	Apr	CAHN
>D>	+	CORNERSTONE THERAP	600MG	N022052	001	May 30, 2007	Apr	CAHN

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

AB		INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	NEWA
AB			5MG	A204284	002	Apr 09, 2014	Mar	NEWA
AB		TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb	NEWA
AB			5MG	A090861	002	Mar 04, 2014	Feb	NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

>A>	@ VIVIMED LABS	5MG	A 076062	001	Apr 23, 2007	Apr	CAHN
>A>	@	10MG	A 076062	002	Apr 23, 2007	Apr	CAHN
>D>	@ WORLD GEN	5MG	A 076062	001	Apr 23, 2007	Apr	CAHN
>D>	@	10MG	A 076062	002	Apr 23, 2007	Apr	CAHN

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	ANI PHARMS INC	25MG	A 077639	001	Dec 22, 2005	Jan	CAHN
	@	25MG	A 077641	003	Dec 22, 2005	Jan	CAHN
AB		50MG	A 077639	002	Dec 22, 2005	Jan	CAHN
	@	50MG	A 077641	002	Dec 22, 2005	Jan	CAHN
AB		100MG	A 077639	003	Dec 22, 2005	Jan	CAHN
	@	100MG	A 077641	001	Dec 22, 2005	Jan	CAHN
	@ SANDOZ	25MG	A 077644	001	Dec 22, 2005	Feb	DISC
	@	50MG	A 077644	002	Dec 22, 2005	Feb	DISC
	@	100MG	A 077644	003	Dec 22, 2005	Feb	DISC

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DRIXORAL PLUS

@ SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987	Feb DISC
-------------------	----------------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	Feb NEWA
---------------	-----	---------	-----	--------------	----------

	10MG	A202277	004	Mar 11, 2014	Feb NEWA
--	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES

IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	Feb NEWA
---------------	-----	---------	-----	--------------	----------

	10MG	A202277	003	Mar 11, 2014	Feb NEWA
--	------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CARACO	5MG	A077631	004	Jan 11, 2008	Feb DISC
----------	-----	---------	-----	--------------	----------

@	10MG	A077631	003	Jan 11, 2008	Feb DISC
---	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CARACO	5MG	A077631	001	Jan 11, 2008	Feb DISC
----------	-----	---------	-----	--------------	----------

@	10MG	A077631	002	Jan 11, 2008	Feb DISC
---	------	---------	-----	--------------	----------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Jan CRLD
---------------	-----------	---------	-----	--------------	----------

DISOPHROL

@ SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982	Jan DISC
-------------------	-----------	---------	-----	--------------	----------

DRIXORAL

@ SCHERING PLOUGH	6MG;120MG	N013483	003	Sep 13, 1982	Jan DISC
-------------------	-----------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014	Jan NEWA
------------------	------------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM

>A>	ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CMS2
-----	----------------	--------------	---------	-----	--------------	----------

>A>	NEXIUM 24HR					
-----	-------------	--	--	--	--	--

>A>	+ ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CTNA
-----	------------------	--------------	---------	-----	--------------	----------

IBUPROFEN

TABLET;ORAL

IBUPROFEN

AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Mar NEWA
---------------	-------	---------	-----	--------------	----------

MINOXIDIL

AEROSOL, FOAM;TOPICAL

WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014	Feb NEWA
-----------------------	----	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2014

NO APRIL 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8653061	Aug 24, 2025	U-1373			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - ADAPALENE</u>						
A 200298 001					>A> PC	Oct 25, 2014
<u>ADENOSINE - ADENOSINE</u>						
A 077425 001					PC	Mar 22, 2014
<u>ALCAFTADINE - LASTACAFIT</u>						
N 022134 001	8664215	Oct 05, 2029	U-1493			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8645160	Jun 18, 2029	U-1485			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	>A> 6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	>A> 6962940	Mar 19, 2023	U-1504			
	>A> 7208516	Mar 19, 2023	U-1505			
	>A> 7427638	Nov 17, 2024	DS DP			
	>A> 7659302	Mar 19, 2023	U-1505			
	>A> 7893101	Dec 09, 2023	DS DP			
	>A> 8455536	Mar 19, 2023	U-1505			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	>A> 6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	>A> 6962940	Mar 19, 2023	U-1504			
	>A> 7208516	Mar 19, 2023	U-1505			
	>A> 7427638	Nov 17, 2024	DS DP			
	>A> 7659302	Mar 19, 2023	U-1505			
	>A> 7893101	Dec 09, 2023	DS DP			
	>A> 8455536	Mar 19, 2023	U-1505			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	>A> 6020358	Oct 30, 2018	DS DP U-1504		NCE	Mar 21, 2019
	>A> 6962940	Mar 19, 2023	U-1504			
	>A> 7208516	Mar 19, 2023	U-1505			
	>A> 7427638	Nov 17, 2024	DS DP			
	>A> 7659302	Mar 19, 2023	U-1505			
	>A> 7893101	Dec 09, 2023	DS DP			
	>A> 8455536	Mar 19, 2023	U-1505			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001					NP	Oct 03, 2016
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	8546428	Mar 19, 2029	DS DP U-1321			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8663699	Jun 03, 2029	U-124			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					>A> PC	Sep 27, 2014
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277			
	8632760	Jan 15, 2023	U-1487			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001					ODE	Jun 20, 2015
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8669290	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8658198	Dec 03, 2027	DP U-1494			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	>A> 8263580	Sep 27, 2028	DP U-1280			
	>A> 8269128	May 26, 2026	DP U-1280			
<u>CERTINIB - ZYKADIA</u>						
N 205755 001	>A> 7153964	Feb 26, 2021	DS DP		>A> NCE	Apr 29, 2019
	>A> 7893074	Apr 25, 2026	DS DP		>A> ODE	Apr 29, 2021
	>A> 7964592	Jan 13, 2027	DS DP			
	>A> 8039479	Jun 29, 2030	DS DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	8003353	Jun 11, 2024	U-817			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001					>A> I-682	Apr 04, 2017
					>A> I-683	Apr 04, 2017
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002					>A> I-682	Apr 04, 2017
					>A> I-683	Apr 04, 2017
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	8663685	Jan 18, 2025	U-1030			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					NCE	Jan 08, 2019
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					NCE	Jan 08, 2019
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	8680103	Feb 04, 2025	DP			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	>A> 6673838	Mar 01, 2022	DS U-860			
	>A> 6673838	Mar 01, 2022	DS U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	>A> 6673838	Mar 01, 2022	DS U-860			
	>A> 6673838	Mar 01, 2022	DS U-1364			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	>A> 6664276	Jan 30, 2023	DS DP U-949			
	>A> 6664276	Jan 30, 2023	DS DP U-950			
	>A> 6664276	Jan 30, 2023	DS DP U-951			
	>A> 6664276	Jan 30, 2023	DS DP U-1507			
	>A> 6664276*PED	Jul 30, 2023				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	>A> 6664276	Jan 30, 2023	DS DP U-949			
	>A> 6664276	Jan 30, 2023	DS DP U-950			
	>A> 6664276	Jan 30, 2023	DS DP U-951			
	>A> 6664276	Jan 30, 2023	DS DP U-1507			
	>A> 6664276*PED	Jul 30, 2023				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992 003					PC	May 18, 2014
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001 >A>	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001 >A>	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002 >A>	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003 >A>	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004 >A>	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005 >A>	8715724	Feb 03, 2028	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					PC	Jun 09, 2014
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP	Mar 20, 2017
					PED	Sep 20, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTECAVIR - BARACLUDE</u>						
N 021798	001				NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655	001	>A> 5690960	Nov 25, 2014	DP U-1509		
		>A> 5714504	Feb 03, 2015	DP U-1509		
		>A> 5877192	May 27, 2014	U-1509		
		>A> 5900424	May 04, 2016	DS U-1509		
		>A> 6369085	May 25, 2018	DS DP U-1509		
		>A> 6428810	Nov 03, 2019	DP U-1509		
		>A> 6875872	May 27, 2014	DS		
		>A> 7411070	May 25, 2018	DS		
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689	001	5877192	May 27, 2014	U-643	D-138	Mar 04, 2017
		5877192	May 27, 2014	U-1495	I-679	Mar 04, 2017
		5877192*PED	Nov 27, 2014			
		6143771	May 27, 2014	DP U-643		
		6143771	May 27, 2014	DP U-1495		
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689	002	5877192	May 27, 2014	U-643	D-138	Mar 04, 2017
		5877192	May 27, 2014	U-1495	I-679	Mar 04, 2017
		5877192*PED	Nov 27, 2014			
		6143771	May 27, 2014	DP U-643		
		6143771	May 27, 2014	DP U-1495		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667	001	>A> 6667050	Apr 06, 2019	DP U-1		
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190	001				>A> ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002	>A> 8722037	Dec 26, 2028	DP		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	001	8617598	Sep 27, 2022	DP		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	002	8617598	Sep 27, 2022	DP		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	003	8617598	Sep 27, 2022	DP		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200	001	>A> 8216180	Jan 12, 2028	DP		
		>A> 8439864	Mar 25, 2028	DP		
<u>EZETIMIBE - ZETIA</u>						
N 021445	001	7612058	Oct 30, 2025	U-1027		
		7612058	Oct 30, 2025	U-1173		
		7612058*PED	Apr 30, 2026			
<u>FENTANYL - SUBSYS</u>						
N 202788	001	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
<u>FENTANYL - SUBSYS</u>						
N 202788	002	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
<u>FENTANYL - SUBSYS</u>						
N 202788	003	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
<u>FENTANYL - SUBSYS</u>						
N 202788	004	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		
<u>FENTANYL - SUBSYS</u>						
N 202788	005	8486972	Apr 27, 2030	DP		
		8486973	Apr 27, 2030	U-55		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001 >A>	6599498	Jun 30, 2023	DS DP			
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	7907135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001					NP	May 10, 2016
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001 >A>	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	>A> 8686034	Jan 24, 2025	U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002 >A>	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	>A> 8686034	Jan 24, 2025	U-1247			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	6054430	May 24, 2014	DS		NP	Jan 28, 2017
	6342476	May 24, 2014	U-441			
	6362161	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
	8232250	Aug 19, 2030	U-441			
	8367605	May 24, 2014	DS			
	8399413	Sep 06, 2030	U-441			
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	8642012	Sep 22, 2030	U-1383			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-680	Feb 12, 2017
	8476284	Dec 28, 2026	U-1491		ODE	Feb 12, 2021
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	001				NP	Jul 26, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	001	RE43932	Jan 16, 2019	DS DP		
		RE43932*PED	Jul 16, 2019			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	002	RE43932	Jan 16, 2019	DS DP		
		RE43932*PED	Jul 16, 2019			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	001				NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	002				NP	Feb 24, 2017
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986	005	6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
	>A>	8672898	Jan 02, 2022	DP		
	>A>	8684969	Oct 20, 2025	DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536	005	6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
	>A>	8672898	Jan 02, 2022	DP		
	>A>	8684969	Oct 20, 2025	DP		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081	002	8679069	Apr 12, 2025	DP		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629	003	8679069	Apr 12, 2025	DP		
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454	001	5310912	Feb 25, 2015	DS		
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528	001	8648107	May 28, 2024	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	001	8637512	Jun 14, 2028	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	002	8637512	Jun 14, 2028	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	003	8637512	Jun 14, 2028	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	004	8637512	Jun 14, 2028	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	005	8637512	Jun 14, 2028	DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	006	8637512	Jun 14, 2028	DP		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	001	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	002	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	003	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	004	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	005	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001 >A>	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	Aug 23, 2027	U-1503			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025	U-1316			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001 >A>	8697686	Dec 20, 2025	DS DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679	Oct 26, 2021	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919 001					>A> ODE	Apr 28, 2021
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001 >A>	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002 >A>	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003 >A>	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004 >A>	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006 >A>	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007 >A>	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008 >A>	8722650	Jun 24, 2025	U-1078			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001 >A>	8685443	Jul 03, 2025	U-1508			
	>A> 8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002 >A>	8685443	Jul 03, 2025	U-1508			
	>A> 8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003 >A>	8685443	Jul 03, 2025	U-1508			
	>A> 8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004 >A>	8685443	Jul 03, 2025	U-1508			
	>A> 8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005 >A>	8685443	Jul 03, 2025	U-1508			
	>A> 8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006 >A>	8685443	Jul 03, 2025	U-1508			
	>A> 8685444	Jul 03, 2025	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					>A> PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					>A> PC	Oct 12, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8663680	Feb 13, 2020	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	002				M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	003				M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545	001	>A> 5641805	Jun 06, 2015	U-765	Y	
		>A> 5641805*PED	Dec 06, 2015			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505	001	8642079	Mar 01, 2028	DP		
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080	001	8637540	Nov 26, 2023	DP		
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080	002	8637540	Nov 26, 2023	DP		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	001	>A> 5202333	Apr 13, 2015	DS DP	U-528	
		>A> 5202333*PED	Oct 13, 2015			
		>A> 7947724	Jan 30, 2024	DP		
		>A> 7947724*PED	Jul 30, 2024			
		>A> 7947725	Jan 30, 2024	DP		
		>A> 7947725*PED	Jul 30, 2024			
		>A> 7960424	Jan 30, 2024	DP		
		>A> 7960424*PED	Jul 30, 2024			
		>A> 8518981	Jan 30, 2024	DP		
		>A> 8518981*PED	Jul 30, 2024			
		>A> 8598218	Jan 30, 2024	DP		
		>A> 8598218*PED	Jul 30, 2024			
		>A> 8598219	Jan 30, 2024	DP		
		>A> 8598219*PED	Jul 30, 2024			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372	002	>A> 5202333	Apr 13, 2015	DS DP	U-901	
		>A> 5202333*PED	Oct 13, 2015			
		>A> 7947724	Jan 30, 2024	DP		
		>A> 7947724*PED	Jul 30, 2024			
		>A> 7947725	Jan 30, 2024	DP		
		>A> 7947725*PED	Jul 30, 2024			
		>A> 7960424	Jan 30, 2024	DP		
		>A> 7960424*PED	Jul 30, 2024			
		>A> 8518981	Jan 30, 2024	DP		
		>A> 8518981*PED	Jul 30, 2024			
		>A> 8598218	Jan 30, 2024	DP		
		>A> 8598218*PED	Jul 30, 2024			
		>A> 8598219	Jan 30, 2024	DP		
		>A> 8598219*PED	Jul 30, 2024			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001	8658663	Apr 06, 2029	DS DP	U-904	
<u>PERFLUTREN - DEFINITY</u>						
N 021064	001	8658205	Apr 20, 2019	DP		
		>A> 8685441	Jan 13, 2019	U-665		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	001	8626531	Oct 23, 2020	U-1361		
		8673939	May 15, 2023	U-1360		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	002	8626531	Oct 23, 2020	U-1361		
		8673939	May 15, 2023	U-1360		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	003	8626531	Oct 23, 2020	U-1361		
		8673939	May 15, 2023	U-1360		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026	004	8626531	Oct 23, 2020	U-1361		
		8673939	May 15, 2023	U-1360		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	>A> 5661151	Jul 19, 2019	DS DP U-1454			
	>A> 5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	8679533	Sep 08, 2029	DP U-219			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022			U-257	
	7435734	Oct 21, 2022			U-257	
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
	>A> 8680124	Jul 20, 2028			U-1506	
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8642573	Oct 02, 2029			U-1481	
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029			U-1481	
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	>A> 7566462	Nov 16, 2025	DP		>A> NPP	Apr 23, 2017
	>A> 7566462*PED	May 16, 2026			>A> ODE	Dec 13, 2014
	>A> 7566714	Nov 17, 2024			>A> PED	Oct 23, 2017
	>A> 7566714*PED	May 17, 2025			>A> PED	Jun 13, 2015
	>A> 7612073	Nov 17, 2024			U-1010	
	>A> 7612073*PED	May 17, 2025				
	>A> 7727987	Nov 17, 2024	DP			
	>A> 7727987*PED	May 17, 2025				
	>A> 7947681	Nov 17, 2024			U-1156	
	>A> 7947681*PED	May 17, 2025				
	>A> 8003126	Nov 16, 2025				
	>A> 8003126*PED	May 17, 2015				
	>A> 8067416	Nov 17, 2024			U-989	
	>A> 8067416*PED	May 17, 2025				
	>A> 8318745	Nov 17, 2024	DP			
	>A> 8318745*PED	May 17, 2025				
	>A> RE43797	Nov 17, 2024			U-1156	
	>A> RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-134	May 24, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845	001				D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473	001				D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109	001				D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676	003				PC	Jul 15, 2014
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	001	8618076	Dec 11, 2030	DS DP U-1470		
		8633309	Mar 26, 2029	DS DP U-1470		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	008	8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	009	8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	010	8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923	001	8618141	Feb 11, 2023	U-1480		
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001	6174304	Dec 13, 2015	DP		
		6251091	Dec 09, 2016	DP		
		6280410	Mar 27, 2017	DP		
		6681810	Dec 13, 2015	DP		
		8241243	Aug 10, 2023	DP		
		8491524	Nov 21, 2022	DP		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	5856529	Dec 09, 2017	DS DP U-1486	NCE ODE	Jan 31, 2019 Jan 31, 2021
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710	001				>A> PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710	002				>A> PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710	003				>A> PC	Jul 07, 2014
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001	8623868	Feb 21, 2023	DP		
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088	001	5362718	Feb 15, 2019	DS DP	Y	
		5362718*PED	Aug 15, 2019			
		RE44768	Feb 15, 2019	DS DP		
		RE44768*PED	Aug 15, 2019			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219	001	7718640	Mar 14, 2027	DP	NP	Mar 05, 2017
		8338395	Feb 27, 2026	U-1500		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	001	8626531	Oct 23, 2020	U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	002	8626531	Oct 23, 2020	U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	003	8626531	Oct 23, 2020	U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	004	8626531	Oct 23, 2020	U-1465		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	>A> 6645963	Nov 16, 2018	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020	U-978			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					NP	Dec 18, 2016
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	8673921	Jun 05, 2022	DS DP			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	8450372	Mar 18, 2028	U-892			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	>A> 6750237	Nov 28, 2020	DP			
	>A> 6750237*PED	May 28, 2021				
	>A> 7220767	Nov 28, 2020	DP			
	>A> 7220767*PED	May 28, 2021				

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>